A DOUBLE DOSE OF INEQUALITY:
PHARMA COMPANIES AND THE COVID-19 VACCINES CRISIS
Amnesty International is a movement of 10 million people which mobilizes the humanity in everyone and campaigns for change so we can all enjoy our human rights. Our vision is of a world where those in power keep their promises, respect international law and are held to account. We are independent of any government, political ideology, economic interest or religion and are funded mainly by our membership and individual donations. We believe that acting in solidarity and compassion with people everywhere can change our societies for the better.
EXECUTIVE SUMMARY

METHODOLOGY

1. HUMAN RIGHTS AND ACCESS TO COVID-19 VACCINES
   BACKGROUND
   STATE OBLIGATIONS: THE RIGHT TO HEALTH
   VACCINE DEVELOPERS’ RESPONSIBILITIES: ACCESS TO VACCINES
   HOW STATES AND COMPANIES HAVE FAILED

2. OBSTACLES TO VACCINE SUPPLY
   INTRODUCTION
   INTELLECTUAL PROPERTY RIGHTS
   KNOWLEDGE TRANSFER AND TECHNOLOGY SHARING
   PRICING POLICIES AND PROFIT
   LACK OF TRANSPARENCY
   WHAT COMPANIES SHOULD DO
   RESPONDING TO INDUSTRY ARGUMENTS

3. COMPANY ASSESSMENTS
   ASTRAZENECA
   JOHNSON & JOHNSON
   MODERNA
   NOVAVAX
   PFIZER/BIONTECH
   CONCLUSION

4. THE TOP TEN INVESTORS

5. CONCLUSIONS AND RECOMMENDATIONS
The rapid development of effective Covid-19 vaccines in 2020 gave hope to the world in the darkest days of the deadly pandemic. Ensuring vaccine access for as many people as quickly as possible is the most effective route out of this unprecedented health and human rights crisis. The handful of companies that developed these vaccines at record speeds could, and should, have been heroes, supplying doses fairly around the world and taking all necessary measures to ramp up production.

This report assesses what major western vaccine makers did instead, tracing their business decisions which favoured a small number of wealthier countries, while blocking other manufacturers from producing their own vaccines. This resulted in predictable – and artificial – vaccine scarcity for the rest of the world.

While Europe, the US and a handful of other states emerged from lockdown, enjoying vacations in the summer of 2021, parts of Africa, Asia and Latin America plunged into renewed crises, pushing ill-equipped health systems to the brink and causing tens of thousands of preventable deaths every week.

Of course, this is not only due to actions and omissions of the pharmaceutical industry. Rich states bought up the supply and hoarded doses. But the vaccine manufacturers have played a decisive role in limiting global vaccine production and obstructing fair access to a life-saving health product. Despite receiving billions of dollars in government funding and advance orders which effectively removed risks normally associated with the development of medicines, vaccine developers have monopolized intellectual property, blocked technology transfers, and lobbied aggressively against measures that would expand the global manufacturing of these vaccines. Some companies - Pfizer, BioNTech and Moderna - have so far delivered almost exclusively to rich countries, putting profit before access to health for all.

The path to a more rapid and fair vaccine roll-out is clear. The People’s Vaccine Alliance, of which Amnesty International is a member, has outlined the steps needed for vaccines to be produced rapidly at scale and made available for all people, in all countries, free of charge. The World Health Organization has launched several initiatives to try to get states and companies to pool resources to speed up the production and fair distribution of Covid-19 vaccines. But a nexus of wealthy states and powerful corporations remain unwilling to cooperate in these initiatives, severely undermining their effectiveness.
EFFORTS TO POOL RESOURCES
The WHO and others have launched several initiatives to try to get states and companies to pool resources to speed up the fair distribution of Covid-19 vaccines, with only very limited success:

- The COVAX Facility functions as a global procurement and distribution mechanism through which available doses can be allocated to participating countries, regardless of income levels. It aimed to make 2 billion doses available by the end of 2021, but by the start of August had shipped only 190 million doses.
- The WHO-led Covid-19 Technology Access Pool (C-TAP), was established to pool intellectual property, data and manufacturing processes, licensing the production to other manufacturers and facilitating technology transfer. To date not a single vaccine manufacturer has shared any patents or know-how through C-TAP.
- In April 2021, the WHO announced that it will also facilitate the establishment of hubs to transfer mRNA-vaccine technology and provide appropriate training to manufacturers in low- and middle-income countries. In June 2021, the WHO announced that the first hub will be established in South Africa.

THE CORPORATE RESPONSIBILITY TO RESPECT HUMAN RIGHTS
All businesses have a responsibility to respect human rights wherever they operate in the world. Above all, this responsibility means that companies should “do no harm”. If they discover that they are the cause of human rights abuses, then they must immediately stop their harmful actions and provide remedy.

This is a widely recognized standard of expected conduct as set out in the UN Guiding Principles on Business and Human Rights and the OECD Guidelines for Multinational Enterprises. The corporate responsibility to respect human rights is independent of a state’s own human rights obligations and exists over and above compliance with national laws and regulations protecting human rights.

For the vaccine developers, the responsibility to respect human rights means that they should develop and implement policies that aim to make quality Covid-19 vaccines available, accessible and affordable. They should ensure that they are not creating obstacles and refrain from any action that unduly impacts on states’ abilities to make Covid-19 vaccines available to all.

Amnesty International has assessed six of the companies that now largely hold the fate of billions of people around the world in their hands. They are: AstraZeneca plc, BioNTech SE, Johnson & Johnson, Moderna, Inc., Novavax, Inc. and Pfizer, Inc. These were the six largest vaccine developers by delivery agreements in doses according to the UNICEF’s COVID-19 Vaccine Market Dashboard in July 2021.

- AstraZeneca is a British-Swedish pharmaceutical company that is manufacturing and distributing the coronavirus vaccine developed by the University of Oxford.
- Johnson & Johnson is a multinational corporation headquartered in New Jersey, United States. Its 100% owned subsidiary, the Netherlands-based Janssen Vaccines & Prevention B.V., developed its viral vector Covid-19 vaccine, which is a one-shot vaccine.
- Moderna is a biotechnology company based in Cambridge, Massachusetts, in the USA.
- Novavax is a biotechnology company based in Maryland, USA. In contrast to the other vaccine developers assessed in this report, Novavax’s vaccine candidate has not yet gained regulatory approval for use.
- Pfizer is a US-based multinational pharmaceutical company headquartered in New York, which has partnered with vaccine developer, BioNTech, based in Mainz, Germany.

Drawing on the UN Guiding Principles on Business and Human Rights and other standards, Amnesty International assessed each company’s published human rights policy, pricing structure, their records on intellectual property, knowledge and technology-sharing, the global allocation of available vaccine doses and transparency.

Amnesty International wrote to each company before publication. Five companies – AstraZeneca, BioNTech, Johnson & Johnson, Moderna and Pfizer – responded, along with institutional investors Baillie Gifford, BlackRock and UBS. Amnesty International reviewed the responses, which can be found in Annex, and took appropriate account of information provided in updating its findings.

In addition, Amnesty International reviewed each company’s published human rights policies, sustainability reports, annual reports, corporate filings and press releases, statements in the media and secondary sources related to the vaccine roll-out. Data on vaccine sales, supply commitments, manufacturing licensing agreements and distribution was drawn from Airfinity, a science information and analytics company, as well as the UNICEF and WHO Covid-19 dashboards and other secondary sources. Figures on global deaths and vaccinations are from Oxford University’s Our World in Data.

This report does not assess in detail the Russian and Chinese companies that have successfully developed vaccines as there is a lack of transparency around their operations that makes it impossible to fully compare them to the others.
HUMAN RIGHTS POLICIES
AstraZeneca, Johnson & Johnson, Pfizer and BioNTech have published human rights policies that reference the UN Guiding Principles on Business and Human Rights. Moderna’s human rights policy does not, while Novavax has published a statement referencing its commitment to equitable vaccine access but does not mention human rights. However, all companies have fallen short of their stated human rights aspirations, in some instances with huge gulfs between rhetoric and reality.

FAIR PRICING
AstraZeneca and Johnson & Johnson have committed to producing vaccines on a not-for-profit basis for emergency pandemic use, although lack of transparency on actual costs of production and sources of external funding make these commitments difficult to fully assess. Their prices are, however, at the lower end of the industry spectrum. In contrast, Pfizer/BioNTech and Moderna have charged higher prices for their vaccines, making significant profit. According to the projections from Airfinity, the three companies’ predicted 2021-22 revenue from sales of Covid-19 vaccines totals over US$130 billion. Novavax has not yet begun its vaccine roll-out, so it is not possible to assess its pricing policy.

INTELLECTUAL PROPERTY AND TECHNOLOGY SHARING
All companies assessed have so far refused to participate in internationally coordinated initiatives designed to boost global supply by sharing technology such as C-TAP, and Covid-19 mRNA hubs. All have also opposed proposals to relax intellectual property rules, such as those put forward by India and South Africa to the WTO Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS). None of the companies have issued global, non-exclusive licences to other companies. Johnson & Johnson sees itself as having “an opportunity to positively impact the protection of human rights within our sphere of influence.” But since February 2021 the company has refused to provide a licence to, or share technology with, Canadian company Biolyse. This company had estimated that it could produce up to 20 million doses of Covid-19 vaccines per year and pledged to inoculate the entire adult population of Bolivia. Following this refusal, Biolyse applied for a compulsory licence, yet the Canadian government has not yet responded, and Covid-19 vaccines have not still been added to the list of health products eligible for compulsory licences. In contrast, AstraZeneca has stated that it has shared its technology and knowledge with over 20 supply partners across 15 countries, including four regional sublicensing agreements in Brazil, China, India and Russia.

GLOBAL VACCINE ALLOCATION
Pfizer has said that “fair and equitable distribution was our North Star from day one”; BioNTech has said that it aims to make its vaccines “available worldwide as quickly as possible”; and Moderna has committed to “provide effective and affordable vaccines and therapeutics to all populations”. Yet Pfizer/BioNTech and Moderna have allocated almost all of their vaccines so far delivered to higher income countries. At the beginning of September, 99% of Pfizer/BioNTech deliveries, have been allocated to high and upper-middle-income countries. This is also the case for 88% of Moderna’s to date.

For Johnson & Johnson, 79% of its deliveries to date have been to high- and upper-middle-income countries, though planned deliveries to COVAX and the African Union means that it is orders for the year are more balanced at 53%, if it meets its commitments. In contrast, for AstraZeneca some 34% of its deliveries went to high- and upper-middle-income countries.

Pfizer/BioNTech and Moderna have so far delivered small percentages of their current production into the COVAX Facility. Most doses currently pledged will only be delivered in 2022 – well after many poorer regions have been wracked by further deadly Covid-19 outbreaks. Just 3.4% of Moderna’s 2021 production and 8% of Pfizer/BioNTech’s is due to go COVAX. Novavax has taken a more responsible approach, with over 60% of their agreed sales to date allocated to COVAX.

TRANSPARENCY
One of the major obstacles to ensuring fair access to Covid-19 vaccines is lack of transparency, which makes contracts, pricing, technology and knowledge transfer impossible to accurately map and optimize. Yet no company assessed has fully disclosed the actual costs of production, individual cost items, sources of external funding, prices charged in different countries, contractual terms and conditions, or information about discounting, donations and advance order guarantees.

OVERALL ASSESSMENT
While the vaccine developers claim to respect human rights, all of them - to differing degrees – have failed to meet their responsibilities. Through their actions and omissions, they have ended up causing or contributing to human rights harms suffered by billions of people lacking access to the Covid-19 vaccine. Companies have caused human rights harms through their decisions not to share intellectual property and technology and contributed to violations of the rights to life and health by repeatedly selling most of their scarce stock to wealthier countries, often at significant profit.
Pfizer/BioNTech and Moderna have charged high prices for their vaccines and allocated almost all of vaccines so far delivered (as opposed to pledged) to high-income countries, putting profits before access to essential medicines. Despite the huge potential of Johnson & Johnson’s single-dose vaccine for reaching poorer parts of the world, the company has been slow to move beyond high- and upper-income markets, and has actively obstructed efforts to license its technology. If Novavax is able to follow through on its significant commitments to supply COVAX, this would be a major boost to the scheme and support fair access to essential medicines. While AstraZeneca should be recognized for its approach to the crisis, the scale of the global health emergency requires much greater action from all of the vaccine producers, including AstraZeneca itself, which has opposed measures to share intellectual property, technology and knowhow.

In November 2020, a group of UN human rights experts warned that “industry and private benefit cannot be prioritized over the rights to life and health of billions,” and that business enterprises “should refrain from causing or contributing to adverse impacts on the rights to life and health by invoking their intellectual property rights and prioritizing economic gains.” Regrettably, those words have not been heeded.

THE TOP TEN INSTITUTIONAL INVESTORS

Institutional investors in vaccine manufacturers also have human rights responsibilities. For this report, Amnesty International has identified the ten largest of these - mainly US-based asset managers and banks - which have combined holdings worth more than US$250 billion in the vaccine developers. The single largest is Vanguard Group Inc. which holds shares worth a total of more than US$66 billion in AstraZeneca, Johnson & Johnson, Moderna, Novavax and Pfizer. BlackRock Inc has more than US$62 billion invested in all six featured companies.

These investors and asset managers must assess the extent to which these companies are causing or contributing to human rights harm through their approach to the crisis. Having identified adverse impacts, they should then engage with these companies and exert their leverage to mitigate the impacts.

In the context of the Covid-19 vaccines, the leverage that this small group of institutional investors has is significant. While none of the top ten institutional investors own or manage more than 10% in any one company, the size of their joint holdings, as well as their total portfolios across the whole sector, give them a significant role in the vaccine developers. Combined, for instance, they own or manage 22.7% of AstraZeneca’s shares, 27.9% of Johnson & Johnson’s, 24.6% of Moderna’s, 17.3% of Novavax’s, and 32.7% of Pfizer’s.

Some investors have recognized, at least partially, the need to for them to try to influence the vaccine makers. Almost 150 institutional investors joined a public call in February 2021 for pharma companies to support “a fair and equitable global response to the pandemic”. While in communications with Amnesty International Baillie Gifford, BlackRock and UBS recognized their human rights responsibilities in relation to the pharmaceutical industry, none of the top ten institutional investors or asset managers were among the signatories.

CONCLUSION AND KEY RECOMMENDATIONS

The starkly unequal distribution of Covid-19 vaccines around the globe indicates that states have not taken the necessary steps to ensure that Covid-19 vaccines are available, accessible, affordable and of good quality for everyone without discrimination, in line with their international human rights obligations.

Rather than take concrete measures to ensure global access to Covid-19 vaccines, states with the power to do so have largely left these decisions around availability, accessibility and affordability in the hands of businesses. As this report demonstrates, the failure of businesses to take all steps at their disposal to achieve fair global access to Covid-19 vaccines means that these companies have fallen short of their human rights responsibilities and in so doing have caused and contributed to human rights harms.

To achieve a fair, rapid roll-out, vaccine developers must suspend their intellectual property rights by either issuing global, open and non-exclusive licences or by participating in C-TAP. They must share their knowledge and technology and train qualified manufacturers committed to contribute to the ramp-up of the production of Covid-19 vaccines. They should not seek to use their influence over governments to obstruct measures designed to facilitate intellectual property and technology sharing, such as the proposed World Trade Organization TRIPS Waiver.

With regards to fair pricing policies, companies must not put their economic interests before their human rights responsibilities. Profit must not become an obstacle to states’ capacity to ensure access to the vaccine. All companies must prioritize increasing availability of vaccines in less wealthy regions and countries by devoting a significant share of their 2021 production runs to the COVAX Facility, as well as other initiatives providing vaccines to lower-income countries such as those coordinated by the African Union, and sustaining high levels of deliveries into these mechanism throughout 2022. Transparency across all aspects of vaccine development and delivery is vital for optimizing supply and ensuring fair vaccine allocation.
As market-driven models alone are unlikely to deliver essential medicines in line with international human rights standards, stronger laws and regulations – especially around accessibility and affordability – are needed for states and companies to deliver on their human rights obligations and responsibilities.

100-DAYS COUNTDOWN

In July, a task force set up by the leaders of the WHO, WTO, IMF and World Bank set a target to vaccinate 40% of people in low and lower-middle income countries by the end of 2021, to protect them and others from Covid-19. With 100 days until the end of the year, less than 10% of people in these countries are fully vaccinated, and tens of thousands of people are dying each week.

As the world reaches a critical phase of the pandemic, Amnesty International is launching a campaign calling on states and pharmaceutical companies to deliver 2 billion vaccines to 82 low- and lower-middle income countries over the next 100 days, in order to fully vaccinate an additional 1.2 billion. To reach this goal, companies and states need to adopt a radically different approach to vaccine allocation: companies must distribute 50% of their production to low- and lower-middle income countries, preferably through the COVAX Facility or other multilateral initiatives; states must urgently redistribute hundreds of millions of surplus vaccines currently in their stocks. Only through concerted, coordinated actions will states and companies be able to bridge the gap.
METHODOLOGY

In response to the Covid-19 pandemic, Amnesty International launched a global campaign calling on states and companies to uphold the right to health of millions of people by taking measures to increase the supply and affordability of Covid-19 vaccines, diagnostics and treatments, and to ensure that everyone, everywhere, without discrimination, can benefit from the global efforts against Covid-19.1 In 2020, Amnesty International published a policy briefing, A Fair Shot, Ensuring Universal Access to Covid-19 Diagnostics, Treatments and Vaccines, outlining state obligations and business responsibilities in relation to access to Covid-19 diagnostics, treatments, and vaccines.2

This report focuses on the extent to which leading Covid-19 vaccine developers are meeting their responsibility to respect human rights. Amnesty International selected the six largest vaccine developers by delivery agreements in doses according to the UNICEF’s COVID-19 Vaccine Market Dashboard as of 20 July 2021.3 These are: AstraZeneca plc (AstraZeneca), BioNTech Manufacturing GmbH (BioNTech), Johnson & Johnson (owner of Janssen Pharmaceutical Companies), Moderna, Inc. (Moderna), Novavax, Inc. (Novavax), and Pfizer, Inc. (Pfizer).4 Amnesty International wrote to each company, asking them a series of questions related to intellectual property, sharing of technology and know-how, pricing and vaccine allocation. At the time of writing AstraZeneca, Moderna, and Pfizer have replied. The substance of their responses has been incorporated into the report. Full replies can be found in Annex 2.

Amnesty International reviewed each company’s response, their published human rights policies, sustainability reports, annual reports, U.S. Securities and Exchange Commission (SEC) filings, corporate press releases, statements in the media and secondary sources related to the vaccine roll-out.5 Drawing on the UN Guiding Principles on Business and Human Rights (UN Guiding Principles) and other standards, Amnesty International assessed each companies’ human rights policy, vaccine pricing structure, their records on intellectual property and technology-sharing, the fair allocation of available vaccine doses and transparency. Amnesty International also identified the ten largest investors in these companies and outlined their human rights responsibilities under the UN Guiding Principles. Information on investor shareholdings is drawn from Bloomberg.

Data on vaccine sales, supply commitments, manufacturing licensing agreements and distribution was drawn from Airfinity, the UNICEF and World Health Organisation COVID-19 dashboards, Knowledge Portal and The Duke Global Health Center’s The Launch and Scale Speedometer and other secondary sources. Figures on global deaths and vaccinations are from Oxford University’s Our World in Data.6

---

1 Amnesty international has also joined the People’s Vaccine Alliance, a worldwide movement campaigning for vaccines to be produced rapidly at scale and made available for all people, in all countries, free of charge. The People’s Vaccine, peoplesvaccine.org/


3 The six largest vaccine developers by delivery agreements in doses according to the UNICEF COVID-19 Vaccine Market Dashboard as of 20 July 2021.


---
Prior to publication, Amnesty International contacted the companies assessed in this report for a second time, along with the top ten institutional investors and asset managers, outlining its main findings and inviting responses. AstraZeneca, BioNTech, Johnson & Johnson, Pfizer, Baillie Gifford, BlackRock and UBS responded.

Amnesty International reviewed the responses, which can be found in annex and took appropriate account of information provided in updating its findings.

This report does not assess in detail the Russian and Chinese companies that have successfully developed vaccines and are currently manufacturing them, as unlike their US, UK and EU-based counterparts, these companies disclose less corporate information. This lack of transparency makes it impossible to fully compare them to the others.
1. HUMAN RIGHTS AND ACCESS TO COVID-19 VACCINES

“Industry and private benefit cannot be prioritized over the life and health of billions.”

UN Human Rights Experts, 9 November 2020

BACKGROUND

Just weeks after the sequencing of the coronavirus genome was published in January 2020, the pharmaceutical industry and research institutes began developing candidate vaccines. Moving at unprecedented speed, they ran large-scale clinical trials and manufacturing in parallel throughout 2020. In the EU, UK and USA, this immense undertaking was bankrolled by billions of dollars of public funding and advance purchase agreements. For example, the US government’s funding of the development, clinical trials, manufacturing and purchase of Moderna’s vaccine was approximately US$5.75 billion. A further US$1.4 billion funded the development of the Janssen/Johnson & Johnson vaccine. Ninety-seven percent of AstraZeneca’s R&D funding came from government and charitable institutions with the UK government providing US$96.7 million. The Pfizer/BioNTech vaccine benefited from US$443 million in funding from the German government and US$17.3 billion in advance purchase agreements from the EU and the USA. Despite this massive support, these states did not place broader conditions on pharmaceutical companies to ensure they shared their innovations, technology and data with other manufacturers or pursued policies that would ensure a fair vaccine roll-out, in line with their human rights responsibilities. This left vital decision-making on vaccine production, pricing and allocation to the companies themselves.

As the roll-out proceeds, the diligence and innovation that produced Covid-19 vaccines has been lacking in dose allocation. These vaccines are key for the protection of millions of lives. But their delivery has been massively skewed towards wealthy nations – which received doses in far greater quantities and at a much faster rate than poorer ones. For example, as of 6 September 2021, vaccine developers (including those in China and Russia which are not assessed in this report), delivered 71% percent of doses to upper-middle

---

3. In one case, just 248 days after Pfizer announced plans to collaborate with BioNTech, the company submitted to the US Food and Drug Administration (FDA) for emergency use authorization, see Edited Transcript PFE-N - Q4 2020 Pfizer Inc Earnings Call, 2 February 2021, s21.q4cdn.com/317678438/files/doc_financials/2020/q4/PFE-USQ_Transcript_2021-02-02.pdf
8. UN Human Rights Experts, 9 November 2020

---

INDEX: POL 40/4621/2021
MONTH/ YEAR SEPTEMBER 2021
LANGUAGE: ENGLISH

amnesty.org
or high-income countries.\textsuperscript{15} When in June 2021 world leaders at the G7 summit discussed the state of the Covid-19 vaccine roll-out, the English county of Cornwall, where the G7 Summit took place, and which has a population of just over half a million, had administered more vaccinations than 22 African countries combined.\textsuperscript{16}

By September 2021, the World Health Organization (WHO) had officially recorded over 4.5 million Covid-19-related deaths,\textsuperscript{17} but the true figure is likely to be much higher. On 15 May 2021 the Economist published modelling which factored in excess death data, suggesting that 10 million or more may have died from Covid-19, with most of the uncounted deaths in low- or middle-income countries.\textsuperscript{18}

“Billions of people in the Global South are being left behind. They see vaccines as a mirage or a privilege for the developed world,” a group of UN experts said on the eve of the June 2021 G7 summit. “This situation will unnecessarily prolong the crisis, drastically increase the death toll and deepen economic distress, possibly sowing the seeds of social unrest.”\textsuperscript{19}

### POOLING RESOURCES FOR DOSE DISTRIBUTION AND INCREASED MANUFACTURING CAPACITY

The WHO and others have launched several initiatives to try to get states and companies to pool resources to speed up the fair distribution of COVID-19 vaccines, with only very limited success:

- \textbullet{} In April 2020, Gavi, the Vaccine Alliance, which includes the WHO, launched the “Access to COVID-19 Tools Accelerator” to facilitate access to Covid-19 health products around the world.\textsuperscript{20} One of its pillars, the Covid-19 Vaccines Global Access (COVAX) Facility, functions as a global procurement and distribution mechanism through which available doses can be allocated to participating countries, regardless of income levels, at the same rate, proportional to their total population size.\textsuperscript{21} Gavi stated in September 2021 that the COVAX Facility, which originally aimed to make more than two billion doses available by the end of 2021,\textsuperscript{22} had shipped 243 million vaccines for delivery and expected to deliver further 1.1 billion vaccines by end of 2021. The WHO-led COVID-19 Technology Access Pool (C-TAP), proposed by Costa Rica, was established in May 2020 to promote open science to accelerate the development of Covid-19 health products and facilitate access to the resulting health technologies.\textsuperscript{23} It aims to do this by pooling intellectual property, data and manufacturing processes, licensing the production to other manufacturers and facilitating technology transfer. C-TAP aims to maximise supply and lower the costs, thereby increasing availability and affordability of Covid-19 diagnostics, treatments, and vaccines. However, C-TAP has not got off the ground in any meaningful way. To date only 43 countries have officially expressed support for C-TAP and not a single vaccine manufacturer has shared any patents or know-how through C-TAP.\textsuperscript{24}

- \textbullet{} In April 2021, the WHO announced that it will also facilitate the establishment of hubs to transfer mRNA-vaccine technology and provide appropriate training to manufacturers in low- and middle-income countries. The objective is to produce, export and distribute the Covid-19 vaccine in low and middle-income countries (LMICs), including through the COVAX Facility. The initiative focuses on mRNA technology due to its adaptability to variants of the virus, its efficacy and because many of its technical features are free of intellectual property rights in many countries of the world. For the technology transfer, it will be essential that the technology is either free of intellectual property constraints in LMICs, or that such rights are made available through non-exclusive licences.\textsuperscript{25} In June 2021, the WHO announced that the first hub will be established in South Africa. To date,
none of the vaccine developers whose vaccine is based on the mRNA technology has committed to transfer technology through this hub.

STATE OBLIGATIONS: THE RIGHT TO HEALTH

Every human being is entitled to the enjoyment of the right to health. States have an obligation to ensure that health facilities, goods, and services, including medicines, are available, accessible, acceptable and of good quality - to everyone, without discrimination, irrespective of where they live or their income. 28

Access to a Covid-19 vaccine that is safe and effective is an essential element of the right of everyone to the highest attainable standard of physical and mental health.29 States therefore have an obligation "to take all the necessary measures, as a matter of priority and to the maximum of their available resources, to guarantee all persons access to vaccines against Covid-19, without any discrimination."30 While states should use the maximum of their available resources to secure the right to health, those that are unable to do so must request international cooperation. States in a position to provide technical or financial assistance must cooperate internationally and provide financial and technical support if needed to uphold the right to health, especially in the face of the global spread of disease.31 Transparency and accountability are key principles underpinning state obligations to uphold the right to health, and are particularly relevant in relation to decision-making, communication with stakeholders and access to remedy.32

Furthermore, states have the obligation to protect against human rights abuse by third parties, including businesses.33 To do so, states must take “appropriate steps to prevent, investigate, punish and redress such abuse through effective policies, legislation, regulations and adjudication.”34 This obligation extends extraterritorially where states can control or influence the conduct of corporations within their territory or under their jurisdiction. In the context of the right to health, states should adopt legislation or other measures to ensure that private actors, including companies, conform with human rights standards when providing health care or other services.35 States must therefore ensure that vaccine developers’ operations extend access to Covid-19 vaccines and do not impede their own and other states’ ability to ensure access for all.

VACCINE DEVELOPERS’ RESPONSIBILITIES: ACCESS TO VACCINES

Companies, including pharmaceutical companies, have a responsibility to respect all human rights wherever they operate in the world and throughout their operations. This is a widely recognized standard of expected conduct as set out in international business and human rights standards including the UN Guiding Principles on Business and Human Rights (UN Guiding Principles) and the OECD Guidelines for Multinational Enterprises (OECD Guidelines).36 This corporate responsibility to respect human rights is independent of a

30 CESCR, Statement on universal affordable vaccination against coronavirus disease (COVID-19), international cooperation and intellectual property, 23 April 2021, para 3, docstore.ohchr.org/SelfServices/FilesHandler.axa?enc=4slQ6QSmlBEDzFEovLCuW1AVC1NkPsgJedPF1vFPMKseuUUC1CIFclakFK95v8Bg4Ik7k7Q18EdfpmCITMnv1VDr1Hl0e1N189AihQ8O2hKpuBKCVhETpIGUieZd
31 OHCHR, General Comment, para 47.
33 CESCR, Statement on the Coronavirus Disease (COVID-19) Pandemic and Economic, Social and Cultural Rights, para 19, The duty of international assistance and cooperation is also highlighted in articles 2.1 and 11.1 of the ICESCR.
35 UN Guiding Principles on Business and Human Rights (UN Guiding Principles), Principle 1
36 UN Guiding Principles, Principle 1
The responsibility to respect human rights requires companies to avoid causing or contributing to human rights abuses through their own business activities, and address impacts in which they are involved, including by remediating any actual abuses. It also requires companies to seek to prevent or mitigate adverse human rights impacts directly linked to their operations, products or services through their business relationships, even if they have not contributed to those impacts.\(^{40}\)

The UN Guiding Principles establish that to meet their corporate responsibility to respect, companies should have in place an ongoing and proactive human rights due diligence process to identify, prevent, mitigate and account for how they address their impacts on human rights. When conducting human rights due diligence, a company may identify that it may cause or contribute to – or already be causing or contributing to – a serious human rights abuse. In these cases, companies must cease or prevent the adverse human rights impacts.\(^{41}\) Where impacts are outside of the business enterprise’s control but are directly linked to their operations, products or services through their business relationships, the UN Guiding Principles require the company to seek to mitigate the human rights impact by exercising leverage, or seek to improve leverage where leverage is limited, including through collaboration if appropriate.

For pharmaceutical companies developing and manufacturing vaccines in the context of the global health crisis, this means that all decisions and actions related to the vaccine roll-out should be rigorously assessed through proactive, ongoing human rights due diligence. Vaccine manufacturers should directly address gaps in policy and practice by developing and implementing policies that aim to make Covid-19 vaccines available, accessible, and affordable. They should remove all obstacles and refrain from any action that unduly impacts on states’ ability to make Covid-19 vaccines available to all. Failures to take the steps needed to ensure fair and comprehensive vaccine roll-out may result in companies causing or contributing to human rights harms. Further guidance for vaccine developers was provided in the UN Human Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines (The Guidelines for Pharmaceutical Companies) in 2008.\(^{42}\) These state that businesses have a “human rights responsibility to extend access to medicines for all including disadvantaged individuals, communities and populations.”\(^{43}\) They should develop and implement policy on access to medicines, considering all arrangements at their disposal to ensure that these are affordable to as many people as possible. The Guidelines for Pharmaceutical Companies specify that businesses should take into account: (i) a country’s stage of economic development; (ii) the differential purchasing power of populations within a country; and (iii) the rights, needs, and challenges of populations that may be at heightened risk of vulnerability and marginalization.\(^{44}\) In line with these considerations, the Guidelines for Pharmaceutical Companies recommend “as part of its access to medicines policy, the company should issue open a non-exclusive voluntary licence...".\(^{45}\)

**HOW STATES AND COMPANIES HAVE FAILED**

As of September 2021, Covid-19 has led to over 4.5 million deaths and 220 million cases worldwide.\(^{46}\) While the world faces the spread of variants and 270 million people are expected to face life-threatening food shortages throughout 2021 - an 80% increase from before the pandemic,\(^{47}\) the unequal global roll-out of Covid-19 vaccines is a stark reminder of how this pandemic has magnified inequalities especially for marginalized populations in lower income countries.\(^{48}\) Countries with wide access to vaccines, such as the UK and the USA, have been able to lift restrictions sooner while countries that have limited to no access to Covid-19 vaccines have faced increasingly severe outbreaks of cases. For example, from April to July 2021, Nepal faced one of the most severe outbreaks along with a shortage of oxygen and vaccines. As of July, Nepal had only fully vaccinated less than three percent of its population, while some wealthy countries enjoyed over 50% vaccination coverage.\(^{49}\)

\(^{38}\) UN Guiding Principles, Principle 11 including Commentary.

\(^{39}\) UN Guiding Principles, Principles 11 and 13 including Commentary.

\(^{40}\) UN Guiding Principles, Principle 19 including Commentary.


\(^{42}\) OHCHR, Human Rights Guidelines for Pharmaceutical Companies, Guidelines, 38.

\(^{43}\) OHCHR, Human Rights Guidelines for Pharmaceutical Companies, Guidelines 5, 30 and 33.

\(^{44}\) OHCHR, Human Rights Guidelines for Pharmaceutical Companies, Guideline 33.

\(^{45}\) On 8 September 2021, the WHO reported 221,648,869 confirmed cases of COVID-19, including 4,582,338 deaths, see WHO, Coronavirus (COVID-19) Dashboard, covid19.who.int/

\(^{46}\) World Food Programme, WFP Global Operational Response Plan, June 2021, p. 5-10, docs.wfp.org/apoids/documents/WFP-0001290222/download?_ga=2.212633428.1908339400.1624214515-1052469607.1623686526


INDEX: POL 40/4621/2021
MONTH/YEAR SEPTEMBER 2021
LANGUAGE: ENGLISH
amnesty.org
This starkly unequal distribution of Covid-19 vaccines around the globe indicates that states have not taken the necessary steps to ensure that Covid-19 vaccines are available, accessible, affordable, and of good quality for everyone without discrimination, in line with its international human rights obligations. Moreover, the United Nations Committee on Economic Social and Cultural Rights has established that these obligations extend extraterritorially. This means that states must provide financial and technical support to uphold the right to health, especially in the face of the international spread of disease. Any such measures could include the sharing of research, knowledge, medical equipment, and supplies. States should ensure that no decision or unilateral measure obstructs access to essential health products and any restriction based on the goal of securing national supply must be proportionate and consider the urgent needs of other countries.

Yet, these extraterritorial state obligations have not been met. Rather than take concrete measures to ensure global access to Covid-19 vaccines, states with the power to do so have largely left these decisions around availability, accessibility, and affordability in the hands of businesses, which also have a responsibility to respect human rights, as outlined in the UN Guiding Principles and the Human Rights Guidelines for Pharmaceutical. As this report demonstrates, the failure of businesses to take all steps at their disposal to achieve fair global access to Covid-19 vaccines means that these companies have fallen short of their human rights responsibilities and in so doing have caused or contributed to human rights harms.

2. OBSTACLES TO VACCINE SUPPLY

INTRODUCTION

“We have all the tools to tame this pandemic everywhere in a matter of months. It comes down to a simple choice: to share or not to share.”

Director General of the World Health Organization, Dr Tedros Adhanom Ghebreyesus51

There are many reasons why the global roll-out of vaccines has been so uneven. High income countries bought up the first tranche of supplies from the major US and European vaccine manufactures even before the vaccines had been approved for use.52 For example, by December 2020, Canada had already secured more than five doses per head of population, the UK over four.53 Rich countries have continued to stackpile well beyond their immediate needs. Some US states now hold more vaccine doses than they can administer, risking significant wastage as stocks reach their expiry date.54

However, vaccine developers have also played a key role in creating unequal access to vaccines by refusing to acknowledge intellectual property as a barrier, failing to sufficiently and swiftly share technology and knowledge needed to increase supply, and failing to divulge vital information about contracts, pricing, and dose allocation. These actions and omissions have created obstacles to fair access to Covid-19 vaccines, skewing the distribution of them to wealthier countries.

This is why Amnesty International has joined forces with the People’s Vaccine Alliance, calling on all pharmaceutical companies manufacturing Covid-19 vaccines to openly share their technology and intellectual property through the World Health Organization COVID-19 Technology Access Pool and other sharing mechanisms, so that billions more doses can be manufactured and safe and effective vaccines can be available to all who need them.55 As a part of the People’s Vaccine Alliance, Amnesty International is also calling on governments to support South Africa and India’s proposal to the World Trade Organization Council to waive intellectual property rights for Covid-19 vaccines, tests, and treatments until everyone is protected. Waiving intellectual protections around rights, combined with technology transfers and coordination by the WHO, can ramp up spare capacity and empower poorer regions which have found themselves dependent on decision-making in a handful of large pharmaceutical companies.

INTELLECTUAL PROPERTY RIGHTS

Efforts to ramp up manufacturing of Covid-19 vaccines face a complex web of global and national legal limitations as the composition of vaccines and their manufacturing processes are often protected by multiple types of intellectual property rights including patents. These allow the creators of a product to restrict the sharing of data around research, development and manufacturing. Patent holders have

52 Launch and Scale Speedometer, Tab. 1.2 Timeline of COVID vaccine purchase deals, launchandscalefaster.org/covid-19/vaccinepurchases
53 Launch and Scale Speedometer, Vaccination Coverage by Population and COVID-19 Burden, launchandscalefaster.org/covid-19/vaccinepurchases
55 The People’s Vaccine, peoplesvaccine.org/
exclusive rights which allow them to set prices for a period of time. The patented product cannot be produced, imported, sold without the patent holders’ permission. Companies also often claim manufacturing steps and clinical data as trade secrets, preventing others from learning and using them for production.56

Intellectual property rights can therefore limit the availability, accessibility and affordability of vaccines by preventing other manufacturers from production. The World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) foresees flexibilities to the strict protection of intellectual property rights, allowing states to amend their laws to better fulfill their public health obligations and provide medicines for all. For example, these flexibilities allow states to determine patentability criteria, issue compulsory licences, and place limitations on, or make exceptions to, exclusive rights, among other measures. However, these flexibilities have proven unsuitable and insufficient during health emergencies, given that these are time-consuming processes that often must be carried out on a country-by-country, case-by-case, and drug-by-drug basis.58

To address these challenges, in October 2020, India and South Africa submitted to the WTO TRIPS Council a proposal to allow countries to temporarily waive certain provisions, including those concerning patents and undisclosed information, of the TRIPS Agreement for the prevention, containment and treatment of Covid-19.59 The goal of the proposal was “to mobilise global manufacturing capacity and to diversify supply options.”60 The current proposal suggests the waiver to last for at least three years.61 Lifting restrictions around intellectual property rights would remove legal barriers that currently impede qualified manufacturers from producing Covid-19 vaccines and other important health products such as diagnostics and treatments. Equally, governments would have the space to intervene to facilitate exports or technology transfer without trade retaliation.

The campaign to waive certain intellectual property protections received a boost in May 2021, when the US government expressed support, albeit only with regards to vaccines and not other products.62

As of August 2021, a revised proposal had over 60 co-sponsors, and over 100 of 164 WTO member states supporting the initiative. However, the European Union (EU) and states such as Switzerland, Norway and the UK, still opposed it.63 The EU tabled its own proposal aiming to maintain the current rules and the use of compulsory licences.64

The pharmaceutical industry has also firmly opposed this proposal. Leading companies, acting through industry organizations including the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), Biotechnology Innovation Organization (BIO), and the European Federation of Pharmaceutical Industries and Association (EFPFIA) have lobbied governments and made numerous statements in the media opposing the TRIPS waiver. In March 2021, PhRMA sent a letter to US President Biden calling for the USA to support “innovation and American jobs by continuing to oppose the TRIPS IP waiver.”65 PhRMA has also started a digital advertising campaign targeting the US decision to support a waiver

56 WTO, Agreement on Trade-Related Aspects of Intellectual property Rights as Amended by the 2005 Protocol Amending the TRIPS Agreement, Article 28.
58 Sustainable Development Goal 3 notes the importance of these flexibilities to provide access to affordable essential medicines and vaccines for all, emphasizing the right of developing countries to tap into these flexibilities. However, developing countries have long faced political and economic pressure from high income countries not to make use of the TRIPS flexibilities. Under Article 31bis of the TRIPS Agreement, which establishes rules for compulsory licensing particularly with regard to the protection of public health, only one compulsory licence for pharmaceutical product has ever been granted. TRIPS flexibilities also apply on a country-by-country, and product-by-product basis and are considered over complicated and impractical, making them ill-suited and too time-consuming for use in a health crisis. Indeed, despite a number of countries having made changes to their domestic legislations that would allow the issuing of compulsory licences or make the process to do so easier, no compulsory licence for a Covid-19 vaccine has yet been issued.
for intellectual property rights of Covid-19 vaccines.67 In May 2021, EFPIA called the Biden administration’s support for the TRIPS waiver a “short-sighted and ineffectual decision”.68 BIO said the Biden administration’s support for the waiver was a “myopic decision” which set a “dangerous precedent”; the organization has argued that a better strategy would be not to diversify global production but to “make the United States the world’s ‘arsenal of vaccines’”.69

**KNOWLEDGE TRANSFER AND TECHNOLOGY SHARING**

The waiver of intellectual property rights could lift legal and bureaucratic deterrents to manufacturing Covid-19 vaccines. Their suspension alone would not, however, automatically accelerate manufacturing and thus increase availability of the Covid-19 vaccine. Vaccines cannot easily be reverse engineered. Their manufacture requires specific expertise and information about production processes.70 Patent applications do not contain all the necessary knowledge and data, because the current intellectual property regime allows companies to shield their trade secrets which can contain all types of commercially-valuable technical, scientific, or engineering information.71 There is also non-codified, tacit knowledge, which can only be transferred through training or staff secondments.72 These gaps must be addressed through sharing of both codified and tacit knowledge, technology transfer, and training – along with the suspension of intellectual property rights.

Knowledge sharing and technology transfer should also aim to geographically diversify production, to address the risks of potential supply blockages. These risks were exposed in March 2021, when the Indian government embargoed the export of Covid-19 vaccines in reaction to a rise in domestic infections, affecting delivery of vaccines to over 60 other countries.73 Diversification could help ramp up spare capacity and empower poorer regions which have found themselves dependent on decision-making in a handful of large companies.

Vaccine developers have so far only shared their knowledge and technology through a handful of bilateral production agreements, but not on a scale which allows sufficient production to meet the current emergency.74 This has led to an unnecessary global shortage of Covid-19 vaccines. Research by Public Citizen has concluded that with adequate resource and knowledge sharing, existing facilities can be repurposed to produce mRNA vaccines in six months – a feat which Moderna itself carried out with the Swiss health care manufacturer, Lonza and which BioNTech achieved by acquiring a manufacturing facility in Marburg.75 Not sharing knowledge and technology to upskill manufacturing capacity is a major omission on the part of the company decision-making, representing a significant obstacle to states’ capacity to respond to the global health crisis and ensure fair access to vaccines around the world. Lack of transparency on potential production sites and agreements also hampers effective use of resources.

**JOHNSON & JOHNSON AND CANADA REJECT EFFORTS TO INCREASE MANUFACTURING OF COVID-19 VACCINES**

Since February 2021, the Canadian pharmaceutical company Biolyse has unsuccessfully attempted to obtain a licence to produce a biosimilar version of the Johnson & Johnson vaccine.76 Johnson & Johnson rejected its request for a voluntary licence with the justification that the company was not exploring new manufacturing in Canada as part of efforts to expand global production for the pandemic. Biolyse subsequently filed for a compulsory licence from the Canadian government, pursuant to the WTO TRIPS Agreement Article 31bis. This stipulation allows countries to grant a compulsory licence to export health products to countries that do not have manufacturing capacity to make these domestically. If granted, Biolyse reported that it could produce up to 20 million doses of Covid-

---

71 WTO, TRIPS Agreement, Article 39m
72 Science, “Knowledge transfer for large-scale vaccine manufacturing,” 13 August 2020, science.sciencemag.org/content/early/2020/08/12/science.abc.9588?version=true
19 vaccines per year and pledged to supply Bolivia with the first 15 million, which could inoculate the country’s entire adult population.  

Despite these attempts, the compulsory licence process has remained at a standstill with no response from the Canadian government. In fact, the Canadian authorities have not added Covid-19 vaccines to its list of health products that are eligible for compulsory licences even though a product can be added to Schedule 1 if it “may be used to address public health problems afflicting many developing and least developed countries, especially those resulting from HIV/AIDS, tuberculosis, malaria and other epidemics”.

As a result, Biolyse has been unable to move forward with their request, which also depends on Johnson & Johnson’s willingness to cooperate with the knowledge and technology transfer that would allow Biolyse to produce in a timely fashion. Meanwhile, Bolivia faces a death toll that is more than double that of Canada’s (1,529 versus 703 cumulative deaths per million people) and only 24.7% of the population is fully vaccinated, while Canada has fully immunized nearly 68% of its people. This inequality is seen across the globe as 78% of vaccine doses have been administered in high- and upper-middle-income countries, while only 0.3% of doses have been given to low-income countries.

**PRICING POLICIES AND PROFIT**

States have the primary obligation to ensure the availability and affordability of Covid-19 vaccines, making them freely available for all those who need them. However, their ability to do so may be impacted by a company’s pricing of vaccines. The higher the costs for procuring vaccines, the higher the risk of limiting a state’s ability to purchase sufficient quantities of Covid-19 vaccines. High prices might even make Covid-19 vaccines inaccessible to countries that cannot afford them.

This is in a context where the vaccine developers received significant public and philanthropic subsidies, as well as advance orders. These reduced or even eliminated the risk that is typically linked to investment in the research and development of a vaccine.

According to the Guidelines for Pharmaceutical Companies, companies should consider all the arrangements at their disposal to ensure that its medicines are affordable to as many people as possible. Given the millions of lives at stake, companies should approach pricing arrangements with “urgency, creativity and boldness”. Companies should pay particular attention to ensuring its medicines are accessible to disadvantaged individuals, communities, and populations, including those living in poverty and the very poorest in all markets. The arrangements should include, for example, differential pricing between countries.

While pharmaceutical companies, such as Pfizer and Moderna, claim they are adopting responsible pricing policies, they are also making enormous profits. Pfizer has reported US$3.5 billion in revenues from the sale of its Covid-19 vaccine, with a projected revenue of $33.5 billion from the Covid-19 vaccine for 2021 (with the gross margin to be split evenly with BioNTech). Moderna’s revenue has increased exponentially since the development of its Covid-19 vaccine, from US$67 million in the second quarter of 2020 to US$4.4 billion in the same period of 2021. While there is little transparency around profits on Covid-19 vaccine sales, Pfizer has stated its pre-tax margin for the Covid-19 vaccine “to be in the high 20s as a percentage of revenue, factoring in manufacturing and distribution costs, royalty expenses, shared R&D expenses and a 50% gross margin split with BioNTech”. On pricing and profit, Pfizer disputed that the company had “disproportionally gained as the result of the Covid-19 vaccine”. According to estimates based on

80 OHCHR, Human Rights Guidelines, Commentary to Guidelines 33-38.
81 OHCHR, Human Rights Guidelines for Pharmaceutical Companies, Guideline 33.
82 Pfizer told Amnesty International that “we priced our vaccine consistent with the urgent global health emergency” using a tiered pricing model. Moderna has said it uses a differential pricing framework. Letter from Dr. Albert Bourla to Amnesty International, 15 June 2021, on file.
84 Pfizer, “Pfizer reports second-quarter 2021 results”, 21 July 2021, on file.
research by Public Citizen, producing the Pfizer/BioNTech vaccine at mass scale could cost as little as US$1.20 per dose to manufacture – a calculation disputed by Pfizer - and the Moderna vaccine around $2.85 per dose.87 In contrast, Pfizer is charging up to US$23.50 per dose in some countries, and Moderna up to US$37. Pfizer has said that it expects to significantly increase prices “beyond a pandemic-pricing environment”, which, combined with lower unit costs from greater volumes, represented “a significant opportunity for […] margins to improve.”88 According to projections by Airfinity in August 2021, Pfizer and Moderna are set to increase revenue in 2022 by 80% and 72%, respectively.89

Writing in November 2020, a group of UN human rights experts has warned that “industry and private benefit cannot be prioritized over the rights to life and health of billions,” and that business enterprises “should refrain from causing or contributing to adverse impacts on the rights to life and health by invoking their intellectual property rights and prioritizing economic gains.”90

VACCINE ALLOCATION AND SEQUENCING

While governments are primarily responsible for ensuring access to medicines, companies have significant decision-making power over the allocation of Covid-19 vaccines through the brokering of advance purchasing agreements, and sequencing of the vaccine production and roll-out. In some situations, governments may end up lacking timely access to vaccines as a result of vaccine developers’ market prioritization.

In prioritizing large scale bilateral agreements with a small number of wealthy countries, companies have focused their limited supply in a way that has put initiatives such as COVAX and poorer countries at the back of the queue. This issue is once more arising in relation to the supply of boosters to low-risk individuals in high income countries.91

In practice, a series of decisions made by both governments and companies has meant that 5.56 billion doses have been administered globally, but only 0.3% of these have been in low-income countries.92 In early September, COVAX had shipped only 243 million doses.93 Pledges for future supplies into COVAX are not addressing immediate, critical need. Moderna, for example, committed 500 million future doses to the COVAX Facility in May 2021, but 446 million (93%) of these will not be delivered until 2022.94 Moderna has so far delivered 84% of its vaccines to high income countries.95

LACK OF TRANSPARENCY

One of the major obstacles to ensuring fair access to Covid-19 vaccines is lack of transparency, which makes contracts, pricing, technology, intellectual property licensing and knowledge transfer impossible to accurately map and optimize. It also undermines the negotiating power of states. What should be a coordinated global effort to address a global health crisis has been overshadowed by a complex series of bilateral negotiations between high-income states and powerful companies.

Vaccine developers have been reluctant to publish commercial contracts, or detailed information on pricing, production, and distribution. In some cases, companies have actively sought to obstruct attempts to access information. For example, Pfizer and Johnson & Johnson have fought requests filed by activist shareholders for the disclosure of information about how public funding will be taken into consideration in the decision-making on access to vaccines and pricing.96 Also contracts between companies and COVAX, CEPI and Gavi have not been disclosed.

As a result, many states have been forced to negotiate contracts blind, unaware of conditions offered in neighbouring countries or other regions. Research carried out in March 2021 by Red Palta, a collaboration of South American newspapers, in partnership with the Argentina-based Fundación Directorio Legislativo, found that 12 governments signed contracts, which agreed to significant concessions while restricting public access to information about the terms agreed, including the prices paid for vaccines in each country.97 Ultimately,
lack of transparency reinforces companies’ control over allocation, weakens governments’ negotiating powers and potentially drives up prices – all of which directly affect a government’s ability to ensure access to Covid-19 vaccines.\textsuperscript{28}

Transparency is a “cardinal principle of international human rights, including the right to the highest attainable standard of health”.\textsuperscript{29} According to the Human Rights Guidelines for Pharmaceutical Companies “the company should be as transparent as possible. There is a presumption in favour of the disclosure of information, held by the company, which relates to access to medicines.”\textsuperscript{100} In the current context, it is key for these companies to publicly disclose disaggregated costs of research, development, production, marketing, distribution, intellectual property licensing and technology transfer information and all other relevant data in a timely and accessible fashion.

**WHAT COMPANIES SHOULD DO**

As part of their human rights responsibilities, pharmaceutical companies should remove obstacles that are hindering the faster and fairer supply of Covid-19 vaccines to all parts of the world. As the UN Guiding Principles set out, “[w]here a business enterprise causes or may cause an adverse human rights impact, it should take the necessary steps to cease or prevent the impact”.\textsuperscript{101}

To begin with, they should forgo the various intellectual property rights needed for vaccine productions. They should not enforce existing intellectual property, refrain from applying and enforcing new intellectual property. Instead they should issue global, open and non-exclusive licences on their patents, know-how and other proprietary technologies, and commit to full transfer of technologies or participate in the WHO COVID-19 Technology Access Pool (C-TAP).\textsuperscript{102} In addition, to concretely accelerate and facilitate production by alternative producers, they should share both their codified and tacit knowledge and technology, as well as train qualified manufacturers committed to contribute to the ramp-up of the production of Covid-19 vaccines. They should do so through C-TAP and, where applicable, cooperating with technology transfer hubs being established by the WHO.\textsuperscript{103}

The companies should also stop lobbying governments to obstruct the TRIPS waiver proposal.\textsuperscript{104} They should not seek to use their influence over governments to obstruct measures designed to facilitate intellectual property and technology sharing, such as the TRIPS Waiver and C-TAP. By exercising their intellectual property rights and blocking access to knowledge and technology, vaccine developers are restricting access to an essential medicine and thereby causing human rights harms.

With regards to pricing, companies must not put their economic interests before their human rights responsibilities. In the context of the current global health crisis, this means that profit must not become an obstacle to states’ capacity to ensure access to the vaccine. When conducting their human rights due diligence as set out in the UN Guiding Principles, vaccine developers must take into account the potential negative impact their pricing policy might have. In line with the Guidelines for Pharmaceutical Companies, the vaccine developer should “give particular attention to ensuring its medicines are accessible to disadvantaged individuals, communities and populations, including those living in poverty and very poorest in all markets”, for example by applying differential pricing between countries or not-for-profit voluntary licensing.\textsuperscript{105}

Vaccine developers must also ensure that the negotiation process of prices with potential purchasing states are aimed at guaranteeing timely availability of the Covid-19 vaccines, and that no delaying tactics are applied to influence pricing. They should make their pricing policies and arrangements transparent, including the actual costs of production, individual cost items, sources of external funding, prices charged in different countries under what contractual terms and conditions, and information about discounting, donations and advance order guarantees.\textsuperscript{106} Transparency in pricing is vital for ensuring fair and open contract negotiations so that buying states are fully aware of market prices and there is consistency around prices charged across and between regions. Lack of transparency can lead to price increases, especially for countries with weak negotiating power.\textsuperscript{107}

Vaccine developers must align their policies and decision-making on vaccine allocation and market prioritization with their responsibility to extend access to vaccines for all. They must identify potential and actual adverse impacts of their vaccine allocation and sequencing

\textsuperscript{98} BMJ, “Price transparency is a step towards sustainable access in middle income countries,” 13 January 2020, www.bmj.com/content/368/bmj.l5375


\textsuperscript{101} UN Guiding Principles, Commentary to Principle 19.


\textsuperscript{104} The Committee on Economic, Social and Cultural Rights (CESCR) has established that intellectual property and patent legal regimes must not undermine the enjoyment of economic, social and cultural rights. Equally, the DOHA Declaration on the WTO’s Trade Related Aspects of Intellectual Property Rights (TRIPS), which regulates the principles of intellectual property protection at an international level, states that the international intellectual property regime should be interpreted in a manner supportive to the protection of public health and in particular to advance access to medicines for all.

\textsuperscript{105} OHCHR, Human Rights Guidelines for Pharmaceutical Companies, Principle 38.

\textsuperscript{106} BMJ, “Pricing of pharmaceuticals is becoming a major challenge for health systems” , 13 January 2020, www.bmj.com/content/368/bmj.14627
choices and put measures in place to mitigate risks and prevent any harm in relation to fair access. Vaccine developers should prioritize increasing availability of vaccines in poorer regions and countries where the roll-out of vaccination has so far been delayed. To ensure fair access to vaccines and distribution to every country in the world, vaccine developers should devote a significant share of their production to the COVAX Facility. By prioritizing rich countries when vaccine supplies are scarce, pharmaceutical companies are contributing to violations of the rights to life and health.

Vaccine developers should engage with states with whom they have previous supply commitments and seek contractual flexibility regarding delivery terms to ensure that those most at risk globally get access to the vaccines in a timely manner, particularly where there are sudden Covid-19 outbreaks requiring urgent responses.

The terms and conditions of some advance purchase agreements prevent states from selling or donating any surplus of Covid-19 vaccine doses to other countries, including for donation via NGOs or the WHO, without prior consent of the manufacturer. These contractual restrictions impede states’ ability to extend access to vaccines. Vaccine developers should immediately lift these barriers.

To extend access to vaccines, vaccine developers should publicly disclose knowledge and technology essential for production of the vaccines in a timely and accessible fashion. Transparency extends to openness about how companies identify and address human rights risks related to their business operations. Under the UN Guiding Principles, the responsibility to respect human rights requires business enterprises to “know and show that they respect human rights in practice.”

**WHAT GOVERNMENTS MUST DO**

The current failure of states to lift intellectual property rights protections that constitute a barrier to scaling up global production of Covid-19 vaccines is a failure of states’ obligation to protect. As the UN Guiding Principles point out, in order to protect against human rights harm by third parties, states must take “appropriate steps to prevent, investigate, punish and redress such abuse through effective policies, legislation, regulations and adjudication.”

States should put measures in place, including legislation, to require vaccine developers to engage in knowledge and technology transfer. They should take an active role in facilitating and resourcing vaccine developers’ sharing capacities, taking into account public funding vaccine developers have already received for the research and development of the Covid-19 vaccines. States should support C-TAP and ensure that vaccine developers in their jurisdiction share knowledge and technology by participating in C-TAP and through other means. States should further support vaccine developers in facilitating cooperation in the supply chain and tackling practical and legal impediments, including lifting export restrictions, and providing financial and technical support to scale up global manufacturing capacity.

States should further ensure the transparency of the Covid-19 vaccine market, in line with the WHO resolution on transparency of the pharmaceutical market, including ensuring transparency of intellectual property licensing through mandatory registration and publication of licensing terms. They must also refrain from taking actions, such as bilateral deals with vaccine developers, that could compromise the ability of other states to extend access to vaccines, which includes “hoarding” of vaccines beyond what is needed for priority, at-risk populations. They should, for instance, bring forward commitments to share doses and allow pharmaceutical companies to prioritize deliveries to poorer and less vaccinated countries. States must cooperate globally and remove any potential barriers to ensure that vaccines are developed and manufactured in sufficient supply, and then distributed in a timely and inclusive manner around the globe.

---

109 UN Guiding Principles, Commentary to Principle 21, f.
110 UN Guiding Principles, Foundational Principles, p. 4.
113 WHO, “WHAT.28.8 - Improving the transparency of markets for medicines, vaccines, and other health products” WHA72.8 - Improving the transparency of markets for medicines, vaccines, and other health products [who.int]

---

**INDEX**

POL 40/4621/2021
MONTH/YEAR SEPTEMBER 2021
LANGUAGE: ENGLISH

amnesty.org
States must condition the public funding of pharmaceutical companies on transparency, knowledge and intellectual property sharing, fair pricing and access to vaccines on the basis of need. This applies particularly to the largest investors in vaccine research and development, such as the EU, the UK and the USA.\textsuperscript{115}

States should share vaccine doses they have purchased to rapidly reach frontline workers and the most vulnerable globally, instead of vaccinating those at home considered low risk.\textsuperscript{116} States should also allow contractual flexibility to the delivery terms of vaccine developers, so that they can deliver doses in response to urgency and need.

**RESPONDING TO INDUSTRY ARGUMENTS**

Major pharmaceutical companies and industry bodies have responded to public pressure for a fairer and faster roll-out with a number of counter arguments, seeking to justify opposition to the proposed TRIPS waiver, and wider knowledge and technology sharing. They have argued that intellectual property, knowledge, and technology sharing will stifle innovation, create competition for scarce raw materials in the supply chain, and will not accelerate global production.

**Innovation and intellectual property protection**

Vaccine developers have argued that “IP is the key driver of innovation” and that waiving these protections will make “it harder to fund research and development into high-risk, high-reward innovations over a long-time horizon.”\textsuperscript{117} This overlooks the fact that scientific innovation for Covid-19 vaccines was largely underwritten by public funding and de-risked through advance orders.\textsuperscript{118}

Furthermore, the proposed TRIPS waiver is time-limited and restricted to Covid-19 related technologies, and thus does not question intellectual property protection as a basic principle or how it applies to other health products. Research on the development of previous vaccines has shown that intellectual property protections, which includes restrictions around knowledge and technology sharing, have reduced supply and kept prices artificially high, impeding access for low- and middle-income countries.\textsuperscript{119}

Vaccine developers also argue that voluntary bilateral licence arrangements with selected partners, often in exchange for payment of a royalty, are the appropriate instrument to overcome intellectual property barriers.\textsuperscript{120} This approach, however, has so far not been sufficient to overcome the persistent imbalance in dose allocation or to meet the global demand for vaccines. Through open and non-exclusive licensing and collaborative mechanisms such as C-TAP, companies could share and license their products to the patent pool, which in turn would make sub-licences available to qualified generics manufacturers, where necessary in return of royalties on sales.

**Supply chain challenges and intellectual property protection**

In an open letter to Pfizer employees, CEO Albert Bourla, argued that the proposed waiver to the WTO TRIPS Agreement would “unleash a scramble for the critical inputs,” and “threaten[s] to disrupt the flow of raw materials”.\textsuperscript{121} Novavax stated that a “TRIPS waiver could further constrain resources by diverting them to entities incapable of manufacturing safe and effective vaccines in the near term.”\textsuperscript{122}

However, challenges in the supply chain cannot be solved by allowing exclusive access to resources to only a limited number of vaccine developers whose joint production capacity does not meet global need. Instead coordinated approaches are required, which aim to

---


address impediments in the supply chain collaboratively. States should support vaccine developers by facilitating cooperation in the supply chain and tackling practical and legal impediments, including removing trade barriers such as export restrictions.\textsuperscript{123} Other raw materials bottlenecks arise from the intellectual property rights architecture itself, which gives a small number of companies exclusive rights over certain essential supply chain technologies and designs. For instance, one of the reasons for shortages of bioreactor bags which are essential hardware for vaccine production is industry consolidation protected by intellectual property rights.\textsuperscript{124} Other bottlenecks are due to political decisions that undermine international cooperation which is vital in times of a public health crisis.\textsuperscript{125}

\begin{center}
\textbf{Global manufacturing capacities and intellectual property protection}
\end{center}

Vaccine developers have argued against waiving intellectual property rights claiming that lifting protections will not automatically accelerate production due to lack of manufacturing expertise and capacity.\textsuperscript{126} However, waiving intellectual property rights must be combined with knowledge sharing and technology transfer to enable other skilled manufacturers to produce the vaccine. Suspending intellectual property protections provides the legal basis for qualified manufacturers to manufacture Covid-19 products without fear of legal reprisal and would allow governments to intervene to facilitate export or technology transfer without trade or legal retaliation.

Experience has shown how adversely intellectual property rights can impact on access to medicines. For a long period, HIV medication was only accessible for a few high-income countries, until generic manufacturing led to dramatically lower prices at the turn of the millennium.\textsuperscript{127} Generic production was then possible in countries where national law did not allow patents on pharmaceutical products. This has changed under the WTO TRIPS Agreement which requires WTO member states to ensure intellectual property rights protection for pharmaceutical products.\textsuperscript{128}


INDEX: POL 40/4621/2021
MONTH/YEAR SEPTEMBER 2021
LANGUAGE: ENGLISH

amnesty.org
3. COMPANY ASSESSMENTS

This assessment covers the six largest vaccine developers by delivery agreements in doses according to the UNICEF COVID-19 Vaccine Market Dashboard as of 20 July 2021: AstraZeneca, BioNTech, Johnson & Johnson, Moderna, Novavax, and Pfizer. Amnesty International assessed the companies’ human rights responsibilities against the UN Guiding Principles on Business and Human Rights (UN Guiding Principles) and related human rights law and standards. The companies were assessed on their human rights policies, their vaccine pricing structure, their records on intellectual property/technology-sharing, fair allocation of available vaccine doses globally and transparency. At the time of writing AstraZeneca, Moderna, and Pfizer, had replied to Amnesty International. Their responses, elements of which have been incorporated into the following assessments, can be read in Annex 2.

ASTRAZENECA

OVERVIEW

AstraZeneca is a British-Swedish pharmaceutical company that is manufacturing and distributing the coronavirus vaccine developed by the University of Oxford. Uniquely among the companies featured in this report, AstraZeneca has pledged to supply its vaccine, “broadly and equitably at no profit during the pandemic.” The company noted that its “aim is to meet an urgent need and support healthcare systems and economies to recover. It is through this that we hope to improve the lives and health of people globally, an objective that is underpinned by our commitment to human rights.”

In the first half of 2021 the company reported revenues of US$15.54 billion - including US$1.169 billion from Covid-19 vaccine, up from $275m in the first quarter. Airfinity estimated AstraZeneca’s revenue from the Covid-19 vaccine would rise to up to US$8.57 billion. AstraZeneca has said it will deliver up to 3 billion doses of Covid-19 vaccine by the end of 2021 by early September, it had delivered 1.9 billion doses according to Airfinity.

HUMAN RIGHTS POLICY

AstraZeneca has published a human rights policy on its website. AstraZeneca states that “health is a human right and therefore enabling access to our medicines is vital,” and that “it is our responsibility to understand how we are contributing to or hindering human rights due to our operations.” AstraZeneca’s human rights policy specifically references the UN Guiding Principles, affirming its responsibility to “prevent human rights violations by proactively identifying any issues in our business and responding promptly with appropriate action.” AstraZeneca has expressed its commitment to “broad, timely and equitable access” to the University of Oxford’s Covid-19 vaccine and to “accelerate vaccine production”, and said that its entire focus “is on playing our part in ending the current pandemic and helping in our shared objective of vaccinating the world.” The policy makes no reference to the Human Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines (Guidelines for Pharmaceutical Companies).

PUBLIC FUNDING AND VACCINE PRICING POLICIES

According to a study published as a MedRxiv preprint on public funding sources for the Oxford-AstraZeneca vaccine and the underlying ChAdOx technology which analyzed peer-review articles published between 2002 and 2020, 97.1% of the R&D funding was from government and charitable institutions mainly from the UK, the USA and the European Commission, with the UK government providing

---

130 Email to Amnesty International, 8 June 2021, on file.
137 AstraZeneca, Human Rights Statement.
138 AstraZeneca, Email to Amnesty International, 8 June 2021, on file.
US$96.7 million.130 The US government awarded US$1.3 billion in funding to AstraZeneca for vaccine trials, manufacturing, and distribution of vaccine doses to the US government.140 AstraZeneca reached a US$750m advanced market commitment with the Coalition for Epidemic Preparedness Innovations (CEPI) and Gavi to support the manufacturing, procurement and distribution of 300 million doses in June 2020.141 AstraZeneca has said that “while we cannot comment on behalf of the University of Oxford regarding any public funding received by the University to develop the underlying ChAdOx technology” AstraZeneca continues “incuring significant ongoing R&D costs that are not directly reimbursed by governments.”142

Regarding its pricing policy, AstraZeneca has provided some detail:

“At the start of the pandemic we made a commitment to make the vaccine available to as many countries as possible at no profit to support broad and equitable access around the world. However, given the complexity of global supply chains, cost of the vaccine can vary depending on supply chain, location and volumes requested by countries. This explains price differentiations between different countries. In addition to the manufacturing costs, AstraZeneca is incurring costs globally that include clinical development, regulatory, distribution, pharmacovigilance and other expenses.”143

However, AstraZeneca has not disclosed the actual costs of production, individual cost items, sources of external funding, prices charged in different countries, or contractual terms and conditions, and information about discounting, donations, and advance order guarantees. This makes it hard to assess its commitment to providing the vaccine at no profit during the pandemic.

Numerous media reports show that prices charged for some vaccines manufactured under licence by the Serum Institute of India (SII) under the brand name COVISHIELD™ have been more expensive than otherwise charged when manufactured by AstraZeneca and other subcontractors.144 This has resulted, for example, in South Africa, Mexico, Brazil, Bangladesh and Uganda, which are low-to-middle-income countries, paying more than high-income countries in the European Union. AstraZeneca has said that the India Serum Institute’s “COVISHIELD™ is priced “according to our global no profit commitment” and that any pricing differential is due to “supply chain, location and volumes requested by countries”145. The AstraZeneca’s vaccine is currently priced at between US$2.12 and US$8 per dose.146

AstraZeneca’s pricing commitment extends to “the pandemic period,” while its partner the University of Oxford stated that a “key element of Oxford’s partnership with AstraZeneca is the joint commitment to provide the vaccine on a no-for-profit basis for the duration of the pandemic across the world, and in perpetuity to low- and middle-income countries.”147 CEO Pascal Soriot has said: “We can’t be at no profit for ever, but we will never intend to make large profits. We’ll definitely have affordable prices, which tier the pricing at different levels depending on the wealth of the various countries.”148 It is unclear what prices will be charged “post-pandemic,” or how “post-pandemic” will be defined.149

INTELLECTUAL PROPERTY RIGHTS AND KNOWLEDGE/TECHNOLOGY SHARING

130 Cross et al., “Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? Approximating the funding to the University of Oxford for the research and development of the ChAdOx1 vaccine”, 10 April 2021, preprint, MedRxiv, doi.org/10.1101/2021.04.08.21255103
142 AstraZeneca said on the issue of public funding that “AZOxford received funding from the UK Government that covered the majority of Oxford’s costs specific to AZD1222, but AstraZeneca has not received any funding from the UK Government for its own R&D costs incurred since the partnership was formed. AstraZeneca also received support from the US Government for the development programme of the vaccine including a Phase 3 clinical trial, but no direct funding to cover the R&D costs of the vaccine has been received by any other government.” AstraZeneca, Email to Amnesty International, 13 September 2021, on file.
144 AstraZeneca, Email to Amnesty International, 8 June 2021, on file, see AstraZeneca’s full statement on R&D funding in Annex 3.

INDEX: POL 40/4621/2021
MONTH/YEAR SEPTEMBER 2021
LANGUAGE: ENGLISH
amnesty.org
AstraZeneca was assigned exclusive patent rights by the University of Oxford whose default position had originally been to donate intellectual property rights through “non-exclusive, royalty-free licences”. At the urging of the Bill Gates Foundation, which argued that the University of Oxford needed to partner with a pharmaceutical company to bring the vaccine to market, the University subsequently sold exclusive rights to its vaccine technology to AstraZeneca. AstraZeneca has publicly opposed sharing of intellectual property through C-TAP, describing it as a block on innovation. AstraZeneca has also lobbied the US Biden administration to oppose proposals put forward by India and South Africa to the WTO Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) to suspend critical intellectual property provisions of the TRIPS Agreement. A letter signed by its Chief Executive Officer with those of other leading pharmaceutical companies, argued that the sharing of copyrights, industrial designs, patents and trade secrets would not widen distribution of the vaccine. The Pharmaceutical Research and Manufacturers of America, which represents AstraZeneca and other companies, has actively lobbied the US Congress against the TRIPS waiver. In April 2021, AstraZeneca joined other pharmaceutical companies to launch the ‘IP Pact’, a declaration of 10 principles on intellectual property, which promotes intellectual property protection as the ‘cornerstone’ for a “dynamic and thriving research ecosystem.”

AstraZeneca has stated that it has shared its technology and knowledge with over 20 supply partners across 15 countries, including four regional sublicensing agreements in Brazil, China, India and Russia. While AstraZeneca’s licence agreements have contributed to an increased production, including for local markets, its reluctance to issue a global, non-exclusive licences or participate in C-TAP remain barriers to fair access to the Covid-19 vaccine.

**VACCINE ALLOCATION AND SEQUENCING**

According to data gathered by Airfinity, 27.4% of AstraZeneca’s orders for 2021 are for high-income countries, compared to 16.8% for upper-middle-income countries, 33.7% for lower-middle income countries, 1.7% low-income countries and 20.4% for COVAX. In terms of deliveries, including those through COVAX, 18.3% of vaccines delivered by AstraZeneca were in high-income countries, 15.9% were in upper-middle-income countries, 64.5% in lower-middle-income countries and 1.3% in low-income countries. This includes over 66 million doses bought by countries including Australia, Canada, Denmark, France, India, Japan, Mexico, New Zealand and the UK, and then donated either bilaterally or via COVAX.

As of August 2021, over half of the vaccine doses delivered by COVAX had been supplied by AstraZeneca, as donations by the USA of Moderna and Johnson & Johnson vaccines increased their relative proportions. According to data gathered by Airfinity, 27.4% of AstraZeneca’s orders for 2021 are for high-income countries, compared to 16.8% for upper-middle-income countries, 33.7% for lower-middle income countries, 1.7% low-income countries and 20.4% for COVAX. In terms of deliveries, including those through COVAX, 18.3% of vaccines delivered by AstraZeneca were in high-income countries, 15.9% were in upper-middle-income countries, 64.5% in lower-middle-income countries and 1.3% in low-income countries. This includes over 66 million doses bought by countries including Australia, Canada, Denmark, France, India, Japan, Mexico, New Zealand and the UK, and then donated either bilaterally or via COVAX.

**SUMMARY**

AstraZeneca has a human rights policy in place which references the UN Guiding Principles. The company has committed to selling its vaccines at cost price, which is to be welcomed. There is a lack of transparency around its pricing policy, but prices are at the lower end of the industry spectrum. AstraZeneca has provided the majority of the supplies to date for COVAX, though India’s export ban has significantly reduced its capacity to deliver due to a lack of diversification of supply. Over 20% of AstraZeneca’s supply for 2021 is committed to COVAX, and a further 35% is committed to low and lower middle-income countries, which is substantially more than some

---

152 Oxford University Innovation, “Technologies Available”, innovation.ox.ac.uk/technologies-available/technology-licensing/expressed-access-covid-19-related-ip/
154 See comment by Pascal Soriot, CEO of AstraZeneca: “If you don’t protect IP then essentially there is no incentive for anyone to innovate.”, quoted by The Financial Times, “Pandemic recovers wounds on IP rights”, 18 June 2020, www.ft.com/content/ded5cafe-9360-11ea-899a-6f2a20d54625
156 Letter from PhRMA to President Biden, 5 March 2021, patentreview.typepad.com/files/2021-03-05-pharma-letter.pdf
157 The Intercept, “Documents reveal pharma plot to stop generic covid-19 vaccine waiver”, 14 May 2021, theintercept.com/2021/05/14/covid-vaccine-waiver-generic-pharma-lobby/
159 AstraZeneca, Email to Amnesty International, 15 December 2021, on file.
160 AstraZeneca, Email to Amnesty International, 13 September 2021, on file.
161 AstraZeneca, Letter from PhRMA to President Biden, 5 March 2021, patentreview.typepad.com/files/2021-03-05-pharma-letter.pdf
164 Airfinity, Covid-19 vaccines database, 9 August 2021. Note that Airfinity estimates that 75% of COVAX deliveries go to low- and lower middle-income countries.
of its industry peers. AstraZeneca has shared knowledge and technology through more than 20 supply partners, including four regional sublicensing agreements, however the company’s reluctance to share intellectual property more widely and fully cooperate with the WHO’s knowledge-sharing initiatives remain barriers to fair access to the Covid-19 vaccine. Additionally, AstraZeneca’s lobbying activities which aim to discourage countries from supporting the TRIPS waiver are also in conflict with its human rights responsibilities.

JOHNSON & JOHNSON

OVERVIEW

Johnson & Johnson is a multinational corporation headquartered in New Jersey, in the USA, developing medical devices, pharmaceuticals and consumer goods. Its 100% owned subsidiary, the Netherlands-based Janssen Vaccines and Prevention B.V. developed its viral vector Covid-19 vaccine, which was approved in the USA in February 2021 and in the EU the following month. Johnson & Johnson reported US$264 million in sales for its Covid-19 vaccine for the first two quarters of 2021 and has stated that it forecasts $2.5 billion in sales in 2021 with production levels at 500 to 600 million doses. By early September 2021, Johnson & Johnson had delivered just over 109 million doses.

In contrast to other approved vaccines, the Janssen/Johnson & Johnson vaccine is single dose and is easy to store and ship, making it particularly effective for use in remote and marginalized populations and in countries with poorly provisioned health care systems where follow-up doses may be difficult to achieve. Johnson & Johnson has said that the company is “committed to equitable, global access to new COVID-19 vaccines.” Similar to AstraZeneca, the company also pledged to distribute its vaccine “on a not-for-profit basis for emergency pandemic use.”

HUMAN RIGHTS POLICY

Johnson & Johnson has published a human rights policy on its website. The company says that its commitment to human rights is “guided” by the UN Guiding Principles and other international standards. The policy makes no reference to the Human Rights Guidelines for Pharmaceutical Companies. The company states that it sees itself as having “an opportunity to positively impact the protection of human rights within our sphere of influence.”

PUBLIC FUNDING AND VACCINE PRICING POLICIES

Johnson & Johnson has not publicly disclosed the actual costs of production, individual cost items, prices charged in different countries, or contractual terms and conditions, and information about discounting, donations, and advance order guarantees. This makes it difficult to assess its commitment to provide its Covid-19 vaccine on a not-for-profit basis, or what it means when it states that this commitment only extends “for emergency pandemic use.” In its letter to the company, Amnesty International asked whether it intended to increase the price of the vaccine after the pandemic was declared, however that was defined. Johnson & Johnson did not clarify its intention relating to future pricing, but stated that they “currently charge the same not-for-profit price globally.”

Johnson & Johnson (along with Pfizer) has fought resolutions filed by activist shareholders for the disclosure of information about how public funding will be taken into consideration in the decision-making on access to vaccines and pricing. According to the U.S. regulatory agency, the company pledged to deliver 100 million doses as part of the US government’s purchase agreements.

166 AstraZeneca has added that “approximately 62% of the 1.2 billion doses released for supply by AstraZeneca and its sublicense partners have gone to low and middle income countries,” Email to Amnesty International, 13 September 2021, on file.
167 Johnson & Johnson, www.jnj.com
174 Johnson & Johnson, “Better Health for All”, healthforhumanityreport.jnj.com/better-health-for-all
178 Johnson & Johnson, Email to Amnesty International, 14 September 2021, on file.
Department of Health and Human Services and Department of Defense Johnson & Johnson’s subsidiary Janssen Vaccines has received US$456 million for clinical trials and approximately US$1 billion to support manufacture from the US government’s Biomedical Advanced Research and Development Authority (BARDA). According to the Knowledge Portal, Johnson & Johnson’s vaccines have been priced at between US$3.50 - $10. Prices tweeted by a Belgian government minister indicated that the EU has paid US$8.50 per dose; according to UNICEF the African Union and the USA have paid US$10 per dose. While in May 2021, Johnson & Johnson was reported stating that price differentials were due to net costs of the vaccine and production volumes, in September 2021 the company wrote in an email to Amnesty International that the provisional not-for-profit price in Advance Purchase Agreements (APAs) had been agreed not to exceed US$10, but that the price had later been fixed at a lower level. It stated that “the provisional not-for-profit price for our vaccine will not exceed USD $7.50 per dose under these APAs. This pricing applies globally, regardless of country”.

**INTELLECTUAL PROPERTY RIGHTS AND KNOWLEDGE/TECHNOLOGY SHARING**

Johnson & Johnson has refused to share its technology through the WHO’S COVID-19 Technology Access Pool (C-TAP), and lobbied the US Biden administration to oppose proposals put forward by India and South Africa to the WTO Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) to suspend critical intellectual property provisions of the TRIPS Agreement. A letter signed by Johnson & Johnson’s Executive Vice President, along with CEOs from other leading pharmaceutical companies, argued that the sharing of copyrights, industrial designs, patents and trade secrets would not widen distribution of the vaccine. The Pharmaceutical Research and Manufacturers of America, which represents Johnson & Johnson among other pharmaceutical companies, has actively lobbied the US Congress against the TRIPS waiver. In April 2021, Johnson & Johnson joined other pharmaceutical companies to launch the ‘IP Pact’, a declaration of 10 principles on intellectual property, which promotes intellectual property protection as the cornerstone for innovation.

Johnson & Johnson has announced plans to scale up production through partnerships with the US Department of Health and Human Services and the pharmaceutical company Merck. Johnson & Johnson is currently manufacturing its vaccine in France, Germany, India, Italy, the Netherlands, Spain, South Africa and the USA, but has rejected a request for a voluntary licence from Canadian company, Biolyse Pharma which is now seeking a compulsory licence from the Canadian government to manufacture the Johnson & Johnson vaccine to supply Bolivia.

Johnson & Johnson has entered into a limited number of bilateral licence agreements with partners in Europe, North America, India and South Africa. The South African manufacturer has been contracted to ‘fill and finish’ vaccines but had to stall production following the contamination of material during production in Baltimore. An arrangement whereby Johnson & Johnson was shipping millions of Covid-19 vaccine doses to Europe that had been filled and finished in South Africa was suspended after media reports and intervention from the South African president. Johnson & Johnson’s reluctance to issue a global, non-exclusive licences or participate in C-TAP and fully cooperate with the WHO’s knowledge-sharing initiatives remain barriers to fair access to the Covid-19 vaccine. Additionally, Johnson & Johnson’s lobbying activities which aim to discourage countries from supporting the TRIPS waiver are also in conflict with its human rights responsibilities.

**VACCINE ALLOCATION AND SEQUENCING**

Johnson & Johnson has announced plans to supply 500 million doses to the COVAX Facility - a commitment of 200 million doses and an option to procure an additional 300 million doses – as well as a contract for a further 220 million doses for the African Union (AU) with

an option for a further 180 million doses. However the company stated that its deliveries will only commence in the third quarter of 2021, and are predominantly due in 2022.194 Only 50 million doses under the AIU contract are expected to be delivered in 2021.195 Johnson & Johnson has also reached agreements to supply countries including: Brazil (38 million); Canada (38 million); Chile (4 million); Colombia (9 million); the European Union (236 million), New Zealand (5 million), South Africa (31 million); Philippines (5 million); UK (52 million); and the USA (300 million).196

According to data gathered by Airfinity, 46.8% of Johnson & Johnson’s orders for 2021 are for high-income countries, compared to 6.4% for upper-middle-income countries, 26.8% for lower-middle-income countries, 0.6% for low-income countries, and 19.4% for COVAX.197 Deliveries to date are even further skewed towards high-income countries. By 6 September 2021, 67.7% of vaccines delivered by Johnson & Johnson were in high-income countries, compared to 11.4% in upper-middle-income countries, 12.6% in lower-middle income countries, and 8.3% in low-income countries. This includes 20 million doses bought by the US and donated to COVAX, and a further nine million donated bilaterally.198

Slow delivery through COVAX and Johnson & Johnson’s decision to commit over half of its doses in 2021 to high- and upper-middle-income countries show that the company is failing to discharge its human rights responsibilities. This is particularly concerning as there had been high expectations that this vaccine would make a significant impact in effective vaccination rates as a single dose vaccine, allowing more transient populations to become fully immunized with a single shot and achieving higher inoculation rates in a shorter period of time.

**SUMMARY**

Johnson & Johnson has a human rights policy based on international standards of corporate responsibility and the right to health. Like AstraZeneca, it has committed to selling its vaccine on a not-for-profit basis which is a positive step. While difficult to assess due to lack of transparency, Johnson & Johnson vaccines are priced at the low end of the industry spectrum. On dose allocation, a majority of doses so far delivered have been committed to upper-middle- and high-income countries. Johnson & Johnson has made significant commitments towards COVAX and the African Union, but roll-out sequencing means most of these doses will not be delivered until 2022. Given this vaccine’s great potential for reaching poor and remote communities, Johnson & Johnson’s decisions on vaccine allocation represent a missed opportunity for ensuring wide access to essential medicines to those in need. Johnson & Johnson’s reluctance to widely share intellectual property, knowledge, and technology transfers – even when directly requested by Biolyse - and fully cooperate with the WHO’s knowledge-sharing initiatives have reduced potential production and remain barriers to fair access.199

**MODERNA**

**OVERVIEW**

Moderna is a biotechnology company based in Cambridge, Massachusetts, in the USA. Founded in 2010, Moderna is a pioneer in developing mRNA technology.200 It has made no commitment to distribute its vaccine equitably or at cost price, unlike AstraZeneca and Johnson & Johnson. But in contrast to the other vaccine developers, in October 2020, Moderna announced that, “it will not enforce its COVID-19 related patents against those making vaccines intended to combat the pandemic”.201 Moderna has agreements to supply 1 billion doses in 2021, and by 6 September 2021 446.5 million doses had been delivered.202

Moderna’s financial situation has been dramatically improved by sales of its Covid-19 vaccine. It reported a total revenue of $803 million in 2020, compared to only $60 million in 2019.203 More recently it reported that it had received revenues of $4.4 billion for the second

---


quarter of 2021, a huge increase on the US$67 million it reported having earned during the same period in 2020. Moderna, with estimated sales of US$18.4 billion in 2021, could yield profits of US$8 billion. Airfinity has estimated that Moderna’s revenue from Covid-19 vaccines will increase again sharply in 2022, to $25.9 billion.

**HUMAN RIGHTS POLICY**

Moderna has published a human rights policy on its website. This states that human rights are inherent in its “values and our commitments.” The policy recognizes the positive role that Moderna’s vaccines can play in “improving human rights through improved health outcomes.” But the policy makes no reference to the UN Guiding Principles, or the Human Rights Guidelines for Pharmaceutical Companies. On 23 December 2020, Moderna published a document entitled, “Moderna’s Commitment to Vaccines and Therapeutics Access.” This includes a commitment to “provide effective and affordable vaccines to therapeutics to all populations.”

**PUBLIC FUNDING AND VACCINE PRICING POLICIES**

The US government has provided Moderna with substantial support to develop its mRNA-1273 vaccine. The vaccine was “co-developed” with scientists from a US public health institution, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. These agencies also supported the vaccine’s non-clinical studies and clinical trials. Another US governmental agency, the Biomedical Advanced Research and Development Authority (BARDA), also supported clinical trials, as well as “vaccine manufacturing scale up and other development activities.”

BARDA awarded Moderna with a total of $955 million dollars to support the vaccine’s development in April and July 2020. The USA has also committed to purchasing 500 million doses from Moderna, more than any other country. In February 2021, the US federal government announced that its total investment in Moderna, including “vaccine development, clinical trials, manufacturing and purchase” was approximately $5.75 billion. This is on top of up to $125 million that BARDA gave Moderna in 2016 to develop an earlier vaccine. In total, the company announced it had signed purchase agreements worth $19.2 billion in 2021.

Moderna stated it will price its products through differential pricing frameworks, with Gavi-eligible countries getting its lowest prices. Moderna added that this commitment will be subject to an “annual independent third-party audit,” but provided no further information or commitment to make the result of these audits public. Moderna has explained that its pricing strategy has two phases. During the pandemic, as defined by the World Health Organization, the company stated that it “will be responsible on pricing” and price the vaccine “below value” without explaining how this would be defined and calculated. During the next phase, once the pandemic has been declared over, Moderna stated that it will “look to price in line with other innovative vaccines” and take market forces into account.

Moderna has only disclosed certain limited information about the prices it has charged to date and did not respond to an Amnesty International request for transparency on this issue. Moderna has stated that it has charged some governments US$32.7 per dose for small volumes, with lower prices for higher volumes. Up to 31 December 2020 it said it had signed deals with different countries to supply a total of approximately 520 million doses, for US$11.7 billion. This is an average of US$22.5 per dose (US$45 per completed dose).

---

205 Financial Times, “Pfizer expects $15bn in Covid vaccine revenue this year”, 2 February 2021, www.ft.com/content/0ab1b38-401d-40ff-284f-66797904f10e
214 Fifty-seven low-income countries are eligible to apply for vaccine support from Gavi; for country list and criteria see Gavi, “Eligibility”, www.gavi.org/types-support/sustainability/eligibility
216 Moderna, “Second Quarter 2020 Conference Call”, 5 August 2020, edge.media-server.com/mmc/p/e53b826c
217 Moderna, “Second Quarter 2020 Conference Call”, 5 August 2020, edge.media-server.com/mmc/p/e53b826c
218 Moderna, “2020 Annual Report”, investors.modernatx.com/static-files/5105e98c-e3e7-4c09-820b-c03812af8f6b
course). The company had earlier said it had sold the US government 100 million doses for between US$12-15 per dose.223 By contrast, South Africa reported that Moderna had offered it 200,000 doses at US$30- US$42 a dose.224 Moderna charged the EU US$18 per dose, according to a Belgian government official, who tweeted the details, along with a list of prices from other vaccine deals.225 This price was raised to $25.50 per dose in supply contracts concluded at a later stage.226 According to this list, Moderna charged the EU considerably more than any other vaccine developer. According to estimates based on research by Public Citizen, the Moderna vaccine could cost under US$3 per dose to manufacture at large scale, meaning profit margins could be vast.227 Overall, Moderna’s high prices and profits, as well as its lack of transparency on pricing regimes, represent an obstacle to fair, universal access to vaccines.

INTELLECTUAL PROPERTY RIGHTS AND KNOWLEDGE/TECHNOLOGY SHARING

In contrast to the other vaccine developers, Moderna has announced that, “it will not enforce its COVID-19 related patents”.228 Moderna stated that it was also “willing to license our intellectual property for COVID-19 vaccines to others for the post pandemic period.” However, the company has not publicly agreed to share its manufacturing know-how or transfer its technology to other manufacturers through bilateral agreements or via the WHO’s C-TAP or mRNA technology transfer hubs. The company argues these are not “effective ways of rapidly expanding access”.229 In a letter to Amnesty International, the company added that it thought that “weakening intellectual property protections could impede future innovation by making it harder to fund research and development into high-risk, high-reward innovations over a long time horizon.”230 Moderna is also a member of the industry body Biotechnology Innovation Organization (BIO), which has called the proposed TRIPS waiver “a dangerous precedent” and called on the US government to “protect American companies from the coerced transfer of technology by foreign governments”.231

In response to the news that the US government would support the suspension of Covid-19 vaccine patents, Moderna’s CEO, Stéphane Bancel, stated that he was “not losing sleep.” This was because, he argued, “there is no idle mRNA manufacturing capacity in the world. This is a new technology, you cannot go hire people who know how to make mRNA — those people don’t exist.”232 The company has, however, demonstrated itself the possibility of expanding manufacturing and supply. Despite claiming that it was hard to “hire people who know how to make mRNA”, Moderna entered its first external partnership to manufacture its vaccine on 1 May 2020 with Lonza, a Swiss company.233 Moderna also told Amnesty International that it was “engaged in active conversations with governments and private companies in middle- and low-income countries about partnerships to expand the manufacturing process in those countries.”234 The company has said it expects to be able to produce up to 3 billion doses in 2022 by ramping up its voluntary licensing agreements. Moderna’s reluctance to issue global, non-exclusive licences or participate in C-TAP and fully cooperate with the WHO’s knowledge-sharing initiatives, such as the WHO’s mRNA technology transfer hub remain barriers to fair access to the Covid-19 vaccine.

VACCINE ALLOCATION AND SEQUENCING

Moderna has supplied or agreed to supply the vast bulk of its vaccines to wealthy states, hindering fair access to essential medicines. The US has purchased 800 million doses.235 The EU has purchased 460 million.236 Moderna has also reached agreements to supply countries including Australia (25 million), Canada (165 million), Japan (100 million), South Korea (40 million), the UK (17 million), Switzerland (27.5 million), Israel (10 million) and Taiwan (40 million).237 The company has disclosed agreements to supply Colombia (10 million), as well as Qatar, Singapore, the Philippines and Botswana, without providing details.238 Moderna told Amnesty International that it was in talks with India and other countries, however it provided no further details.239

223 United States Securities and Exchange Commission, Moderna Form 8-K, 11 August 2020, , Inc., investors.modernatx.com/static-files/5ca1125f-3452-4a63-b292-cfa5f6ba49e0


226 Financial Times, “Pfizer and Moderna raise EU Covid vaccine prices”, 1 August 2021, www.ft.com/content/4d415a01-e0d5-4a49-baad-8235a804-1a


231 Financial Times, “Moderna CEO ‘didn’t lose sleep’ over US backing of patent waiver”, 6 May 2021, www.ft.com/content/607bf143-3360-4543-8cb4-b11c42f41f


INDEX: POL 40/4621/2021
MONTH/YEAR SEPTEMBER 2021
LANGUAGE: ENGLISH

amnesty.org
In May 2021 — ten months after it began signing supply agreements with high-income countries - Moderna announced that it had reached an agreement to supply 500 million doses to 92 low- and middle-income countries via the COVAX Facility at its lowest price. Moderna stated that this would see it supplying an initial 34 million doses in the fourth quarter of 2021, with an option to eventually supply a further 466 million doses only in 2022.

According to data gathered by Airfinity, 87.5% of Moderna’s orders for 2021 are for high-income countries, compared to 3.6% for upper middle-income countries, 5.5% for lower-middle-income countries, 0.2% for low-income countries and 3.4% for COVAX. In terms of deliveries by September 2021, the proportions are similar, with 84.5% for high-income countries, 3.7% for upper-middle-income countries, 11.8% for lower middle-income countries and 0% for low-income countries. This includes over 43 million doses bought by the USA and donated to COVAX, and a further 15 million doses donated bilaterally.

**SUMMARY**

Moderna has a limited human rights policy which does not reference core international business and human rights standards. It charges relatively high prices for its vaccines, compared to other companies. It has failed to specify its criteria for differential pricing for different countries during the pandemic and has offered little transparency on what this means in practice. While committing to not enforce its patents, this has meant little in practice. Like all companies assessed here, Moderna has not joined C-TAP or the WHO’s mRNA technology transfer hub. The vast majority of Moderna’s orders for 2021, and deliveries to date, are for high-income countries. While it has pledged significant quantities of vaccines to the COVAX Facility, over 90% of these will only be delivered in 2022. Moderna is therefore impeding full and fair access to the Covid-19 vaccine through its policies and practices.

**NOVAVAX**

**OVERVIEW**

Novavax is a biotechnology company focusing on the development of vaccines based in Maryland, USA. In contrast to the other vaccine developers assessed in this report, Novavax’s vaccine candidate has not yet gained regulatory approval for use and therefore vaccine doses have not been distributed. In the second quarter of 2021, the company’s revenue was $298 million, compared to $36 million in the same period in 2020. This increase was due to its activities in relation to its Covid-19 vaccine. According to UNICEF, Novavax has agreed sales of over 2.6 billion doses.

**HUMAN RIGHTS POLICY**

Novavax has not published a human rights policy, but stated the company’s commitment “to ensuring fair and equitable access to our vaccine around the world,” adding that “we have made it among our core values to ensure that those in economically disadvantaged countries have the opportunity to receive our vaccine in parallel with the rest of the world” and “our aim is that NVX-CoV2373 can address the vast global health need and reach countless individuals, regardless of country-specific income.” Novavax makes no reference to the UN Guiding Principles, or the Human Rights Guidelines for Pharmaceutical Companies in its company literature.

**PUBLIC FUNDING AND VACCINE PRICING POLICY**

Novavax has received about US$2 billion external funding; the biggest share of it through the US government’s Operation Warp Speed (US$1.6 billion). Further, the U.S. Department of Defense funds up to US$70 million for the manufacturing of its vaccine. The Coalition for Epidemic Preparedness Innovations (CEPI) agreed to invest up to US$388 million of funding and Novavax has received further US$15 million from the Bill & Melinda Gates Foundation. In its Annual Report section on potential risks, Novavax has listed “decisions we have made and will be making regarding the development, testing, manufacturing, allocation and pricing” as a source of potential reputational harm, given the urgency of the public health emergency and the significant funding the company has received from the US and foreign governments.

---


241 Airfinity, Covid-19 vaccines database, 6 September 2021. Note that Airfinity estimates that 75% of COVAX deliveries go to low- and lower middle-income countries.


243 Novavax, www.novavax.com/

244 Novavax reports Second Quarter 2021”, 5 August 2021, Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights - Aug 5, 2021


In July 2020, Novavax said it is “in the process of developing a thoughtful pricing strategy” and that Novavax’s pricing will be aimed at ensuring “equitable access throughout the globe.” Novavax has said that it expects “to supply doses to primarily high-income countries, with SIIPL [Serum Institute of India, SII] providing the majority of supply for low-, middle-, and upper-middle-income countries, utilizing a tiered pricing schedule” though has not specified how this will operate in practice. Novavax has licensed its technology to SII and “are jointly committed with SIIPL to deliver the 1.1 billion doses to the COVAX Facility” in collaboration with Gavi and the Bill & Melinda Gates Foundation. According to Gavi, the funding by partners such as the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation and SII will ensure that the vaccines will have a ceiling price of US$3 per dose. The USA has made advance purchases agreements at US$16 a dose. Novavax has provided little in the way of information about its pricing policy towards its supplies to other countries, making an overall assessment difficult.

**INTELLECTUAL PROPERTY RIGHTS AND KNOWLEDGE/TECHNOLOGY SHARING**

Novavax states that it is partnering with dozens of organizations around the world to increase manufacturing capacity. This has involved “months transferring know-how to our partners to ensure they are able to manufacture doses that meet regulators’ standards for safety and effectiveness around the world.” Its production is taking place in Canada, the EU, India, South Korea, the UK, the USA and Japan.

Novavax has publicly criticized proposals to waive intellectual property protections for vaccines during the pandemic. It has argued that a “TRIPS waiver could increase national barriers to the free flow of materials and vaccine doses, threatening the stability and integrity of the global supply chain.” Novavax has stated that it had “experienced a shortage of raw materials, which has impacted the timing by which we expect to realize our anticipated total manufacturing capacity.” Novavax has not issued open, non-exclusive production agreements or signed up to participating in C-TAP, potentially creating barriers to fair access to the Covid-19 vaccine.

**VACCINE ALLOCATION AND SEQUENCING**

Novavax states that it expects to apply for regulatory approval in the third quarter of 2021 with production increasing from 100 million doses per month by the end of the third quarter to 150 million doses per month by the fourth quarter. The company states that it projects that it will produce three billion doses worldwide in 2022.

Novavax has provided some details about supply agreements, including its notable pledge to supply countries participating in COVAX with 1.35 billion doses of its candidate vaccine – over 51% of supply commitments to date. It has reached an agreement with the Serum Institute of India to manufacture and distribute 750 million of these. Novavax has also reached agreements to supply Australia (51 million), Canada (76 million), the EU (200 million), Georgia (1 million), Indonesia (130 million), New Zealand (10 million), South Korea (40 million), Switzerland (6 million), the UK (60 million), Ukraine (15 million) and the US (660 million).

According to data gathered Airfinity, 32.8% of Novavax’s orders are for high-income countries, compared to 2.9% for upper-middle-income countries, 0.9% for lower-middle-income countries, 0% for low-income countries and 63.4% for COVAX.

**SUMMARY**

---


261 Reuters, "EU expects key data on Novavax vaccine around October", 20 August 2021, www.reuters.com/business/healthcare-pharmaceuticals/eu-expects-key-data-novavax-vaccine-around-october-2021-08-20/


263 USA Today, "Novavax plans to present US data on its COVID-19 vaccine as soon as this month, but manufacturing will delay deliveries,” 5 May 2021, usatoday.com/story/news/health/2021/05/10/novavax-ceo-request-fda-covid-vaccine-authorization-coming-soon/5023751001/


Novavax has no human rights policy but said it is committed to accelerate fair access to Covid-19 vaccines. If Novavax is able to follow through on its significant commitments to supply COVAX, Novavax’s overall dose allocation would be a major boost to the scheme and support fair access to essential medicines. Novavax’ opposition to the WTO TRIPS waiver and to participation in C-TAP all amount to a barrier to fair access to the Covid-19 vaccine. Due to the lack of transparency and the fact that Novavax has not yet begun its vaccine roll-out, it is not possible to assess Novavax’ pricing policy.

**PFIZER/BIONTECH**

**OVERVIEW**

Pfizer is a US-based multinational pharmaceutical company headquartered in New York. For its second quarterly period in July 2021, Pfizer reported revenues of US$33.6 billion so far this year – a 68% increase compared to the second quarter of 2020 – including US$11.3 billion from sales of its Covid-19 vaccine. It also anticipated revenue of US$33.5 billion from the Covid-19 vaccine for 2021, with the gross margin to be split evenly with BioNTech. As such, Pfizer’s annual total revenue in 2021 is expected to increase by roughly 89% compared to 2020, with revenue from the Covid-19 vaccine accounting for over 87% of that increase. Airfinity estimates for 2022 that Pfizer’s overall revenue will again increase by 80%.

BioNTech is a German pharmaceutical company headquartered in Mainz. BioNTech developed its vaccine using mRNA technology and partnered with Pfizer to assist in clinical trials, manufacture and roll-out. In the second quarter of 2021 BioNTech reported US$8.62 billion (€7.36 billion) in revenues from the sale of its Covid-19 vaccine and pre-tax profits of US$4.57 billion (€3.9 billion). This represents a huge increase from the same period in 2020, when BioNTech reported revenues of US$81.3 million (€69.4 million) and a net loss of US$16.6 million (€14.2 million). BioNTech attributed this huge growth as “mainly due to rapid increases in the supply of Covid-19 vaccine worldwide.”

While there is little transparency around profits on Covid-19 vaccine sales, Pfizer has stated its pre-tax margin for the Covid-19 vaccine “to be in the high 20s as a percentage of revenue, factoring in manufacturing and distribution costs, royalty expenses, shared R&D expenses and a 50% gross margin split with BioNTech.” According to estimates based on research by Public Citizen, the Pfizer/BioNTech vaccines could cost as little as US$1.20 per dose to manufacture, meaning profit margins could be far higher, though Pfizer has said that it has reviewed the cost calculation by Public Citizen and disagrees with their figures. Pfizer has reported that it expects to produce 3 billion doses in 2021. As of early September 2021 it had delivered 1.4 billion doses to over 100 countries.

**HUMAN RIGHTS POLICIES**

Pfizer has published a human rights policy on its website and has committed to “respect internationally recognized human rights throughout our operations.” In a letter to Amnesty International, CEO Dr. Albert Bourla has stated that “the right to health is the most salient human rights issue for Pfizer.” Bourla also wrote in an open letter to staff that “fair and equitable distribution was our North Star from day one.” Pfizer’s policy makes reference to the UN Guiding Principles on Business and Human Rights but does not reference the UN Human Rights Guidelines for Pharmaceutical Companies.

BioNTech has published a section on human rights in its Code of Business Conduct & Ethics on its website. This states that BioNTech’s vision is “to bring highly effective, individualized, and innovative therapies to market and make them available to patients around the world.”

---

270 BioNTech, “Code of Business Conduct & Ethics”, p. 54, investors.biontech.de/static-files/e2ac32b2-96f8-4ef6-a19e-adbec34db8f9
280 Pfizer, “Pfizer reports second-quarter 2021 results”, p. 4, Pfizer, Email to Amnesty International, 13 September 2021, on file.
283 Pfizer, “Pfizer reports second-quarter 2021 results”, p. 4, Pfizer, Email to Amnesty International, 13 September 2021, on file.
288 Pfizer, “Pfizer reports second-quarter 2021 results”, p. 4, Pfizer, Email to Amnesty International, 13 September 2021, on file.
289 Pfizer, “Pfizer reports second-quarter 2021 results”, p. 4, Pfizer, Email to Amnesty International, 13 September 2021, on file.

globe”. The company has said that its goal is making its Covid-19 vaccine “available to the public worldwide as quickly as possible”383 and that it is “firmly committed to working towards equitable and affordable access for COVID-19 vaccines for all people around the world”.384 BioNTech states that it is committed to complying with the UN Guiding Principles and to “prevent or mitigate adverse human rights impacts that are directly linked to our operations, products or services by our business relationships, even if they have not contributed to those impacts.”385 BioNTech’s policy makes no reference to the UN Human Rights Guidelines for Pharmaceutical Companies.386

PUBLIC FUNDING AND VACCINE PRICING POLICIES

Pfizer told Amnesty International that the “development and manufacturing costs relating to the Covid-19 vaccine have been entirely self-funded.”387 However, in July 2020, the US government placed an advance order of 100 million doses for US$1.95 billion, optioning up to 500 million additional doses.388 Other countries made additional advance orders for hundreds of millions of doses.389 Pfizer has also benefited from the public funding of its partner, BioNTech. In the first quarter of 2021, BioNTech received US$88.22 million (€67.9 million) in government grants, part of up to US$443 (€375 million) in funding from the German Federal Ministry of Education and Research to Support Covid-19 Vaccine Programme.390 BioNTech also received up to US$100 million in debt financing from the European Investment Bank to support vaccine development and manufacture.391 BioNTech and Pfizer share research and development costs which rose to US$762 (€645 million) in 2020 largely due to the vaccine program.392

Pfizer (along with Johnson & Johnson) have fought resolutions filed by activist shareholders for the disclosure of information about how public funding will be taken into consideration in the decision-making on access to vaccines and pricing.393

Pfizer/BioNTech, like Moderna, have eschewed the not-for-profit approach adopted by other companies. Pfizer has stated that it follows “a tiered pricing approach that was based on the income level of each country which allowed Governments to distribute our vaccine to their citizens for free”,394 offering its vaccine to low-income countries at cost, while adding increasing profit margins to middle-income and high-income countries.395 In a letter to Amnesty International, Pfizer stated that “we established pricing principles for the Covid-19 vaccine which are consistent with Pfizer’s commitment to the right to health.”396 However, Pfizer’s CEO, Albert Bourla has said that Covid-19 vaccine developers should not forgo profits on products they make and described the vaccine as a “huge commercial opportunity”.397

Pfizer has not explained the rationale of its pricing policy for high and upper-middle-income countries or provided any information on pricing. According to data gathered by Knowledge Portal, prices range from US$6.75 – US$23.50 per dose.398 The African Union (AU) has paid US$6.75 a dose, middle-income countries South Africa and Colombia agreed to a price of roughly US$10 a dose and about US$12 a dose, respectively, with upper-middle-income country Lebanon paying US$18, the United States US$19.91 and Israel

385 BioNTech, “Code of Business Conduct & Ethics”, p. 54, investors.biontech.de/static-files/62ac32b2-96f8-4ef6-a19e-adbec34dd8f9
386 In response to Amnesty International’s findings, BioNTech stated that “A human rights due diligence review is planned for 2021/2022. We will establish policies, governance structures and processes to address human rights and related environmental risks in our operations and value chain and regularly report on implementation. The UN Human Rights Guidelines for Pharmaceutical Companies will be included in this due diligence process.” Email to Amnesty International, 9 September 2021, on file.
389 For a breakdown, see The Lancet, “Data on public and non-profit funding for the research, development and production of COVID-19 vaccines”, 21 February 2021, pp. 8-9, www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)30305-8/fulltext.pdf. Pfizer has stated that “the funds received by Pfizer through advance purchase agreement are payments for vaccine doses that governments are acquiring for their people” and that “these payments are not and should not be considered government subsidies for the research, development and production of the vaccine”. Email to Amnesty International, 13 September 2021, on file.
Pfizer has also stated that prices are likely to increase, “beyond a pandemic-pricing environment”, which, combined with lower unit costs from greater volumes, represented a “significant opportunity for […] margins to improve.” Pfizer cited a typical vaccine price of US$150 or US$175. Pfizer told Amnesty International that “post the pandemic, we will utilize a market and value-based pricing approach”. Pfizer’s substantial profits and high prices in comparison to industry peers remain barriers to fair access to the Covid-19 vaccine.

**INTELLECTUAL PROPERTY RIGHTS AND KNOWLEDGE/TECHNOLOGY SHARING**

Pfizer and BioNTech have opposed C-TAP and have not joined WHO’s COVID-19 mRNA vaccine technology transfer hub. Pfizer has lobbied the US Biden administration to oppose proposals put forward by India and South Africa to the WTO Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) to suspend critical intellectual property provisions of the TRIPS Agreement, which it describes as a disincentive to investment and innovation.

Pfizer replied to Amnesty International that waiving those TRIPS commitments would “send the wrong message to future innovators in the next pandemic” and “could make it harder to resolve the current one, particularly if companies begin to buy up scarce inputs in the hopes of manufacturing a vaccine using technology developed by others”. Pfizer also said that “IP directed to the mRNA COVID-19 vaccine is primarily owned by BioNTech”. On C-TAP, the company added: “Pfizer welcomes voluntary initiatives that add to the pool of resources and options available to promote equitable access to COVID-19 therapies and vaccines, and we remain committed to constructive dialogue with all parties.” However, Pfizer’s Chairman and CEO Dr. Albert Bourla said of WHO voluntary pools “I think it’s nonsense, and… it’s also dangerous,” as companies are “investing billions to find a solution” but that “if you have a discovery, we are going to take your (intellectual property), I think, is dangerous.” In April 2021, Pfizer launched the ‘IP Pact’ jointly with other pharmaceutical companies, a declaration of 10 principles on intellectual property which promotes intellectual property protection as the cornerstone for innovation.

BioNTech has listed “maintaining, defending, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how” as a key success indicator. BioNTech has announced plans to establish mRNA vaccine production facilities in Africa, but CEO Uğur Şahin has stated that this would take up to four years.

BioNTech announced the signing of a letter of intent with The Biovac Institute, a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech Covid-19 Vaccine for distribution within the African Union. Pfizer/BioNTech is currently manufacturing its Covid-19 vaccine in Germany and Belgium, while fill and finish processes are carried out in Belgium, Germany, Switzerland and France.

**VACCINE ALLOCATION AND SEQUENCING**

Pfizer told Amnesty International that it had proactively reached out to governments “to address the risk this imbalance represented to people in lower income countries because the supply was limited” but that for a variety of reasons, including the fact that mRNA technology was then untested, lack of regulatory approval and governments opting for local production, this was not successful.

---


300 Financial Times, “Pfizer and Moderna raise EU Covid vaccine prices”, 1 August 2021, www.ft.com/content/id415a01e-d065-44a9-baad-9235aa04c1a


308 IP Principles for Advancing Cures and Therapies (IP PACT), cdn.pfizer.com/pfizercom/IP_PACT_DOCUMENT_FINAL.pdf


added that “we now expect the supply balance to weigh in favour of middle- and low-income countries in the second half of 2021, and to have virtually enough supply in 2022 for all governments that choose to procure our vaccine.”

On 10 June 2021, the US government announced plans to buy 500 million Pfizer/BioNTech doses at cost for the COVAX Facility. The US government has said that 200 million doses will be shipped in 2021 and a further 300 million in the first half of 2022 to 92 low- and lower-middle-income countries and the African Union. BioNTech stated that the companies “aim to provide 2 billion doses to low- and middle-income countries in 2021 and 2022 – 1 billion each year.

According to Airfinity, the breakdown on 2021 orders of the Pfizer/BioNTech vaccine by income group is 59.9% for high-income countries, compared to 24% for upper-middle-income countries, 7.7% for lower-middle-income countries, 0.01% for low-income countries and 8.4% for COVAX. In terms of the breakdown of deliveries (including through COVAX) up to 6 September 2021 the proportions are even more heavily skewed towards richer countries, with 79.9% for high-income countries, compared to 18.0% for upper-middle-income countries, 2.0% for lower-middle-income countries, and 0.1% for low-income countries. This includes over 9 million doses bought by countries, including the EU and the USA, and donated bilaterally.

**SUMMARY**

Both Pfizer and BioNTech have committed to the UN Guiding Principles in their human rights policies. However, Pfizer has strongly lobbied against the proposed TRIPS waiver and both companies have declined to participate in WHO intellectual property and technology sharing mechanisms. Pfizer/BioNTech have so far delivered almost all of their vaccines to high-income countries and have only belatedly committed significant quantities of doses to the COVAX Facility, the majority of which will not be produced and distributed until 2022. While Pfizer states it has applied a tiered pricing policy, the companies have charged high prices for countries that may appear to have higher-income but face a severe economic crisis such as Lebanon, and mainly delivered its products to high-income countries, putting economic interest before access to Covid-19 vaccines.

**OTHER VACCINE SUPPLIERS: SINOPHARM, SINOVAC BIOTECH LTD AND THE GAMALEYA NATIONAL RESEARCH CENTER**

As of September 2021, 330 vaccine candidates were under development and nearly 100 were in clinical trials. In addition to the companies and vaccines named above, three key vaccines have been widely distributed worldwide. While Amnesty International has not included an in-depth analysis of these companies, below is a summary of their availability across the globe.

In May 2021, the WHO approved for emergency use the Covid-19 vaccine BBP developed by Sinopharm under the state-owned China National Pharmaceutical Group. As of August 2021, Sinopharm had produced nearly one billion doses and announced an increased annual vaccine production capacity of 5 billion doses, which would significantly increase available global supply of vaccines. While Sinopharm has not joined C-TAP, it has signed agreements with several countries to manufacture vaccines such as Bangladesh. So far, the Sinopharm vaccine has been approved for use in Bahrain, China, Egypt, Jordan, Serbia, Iraq, Pakistan, Morocco, Hungary, Peru, Nepal, Argentina, Iran, Jordan, Maldives, Indonesia, Bangladesh, Thailand, Vietnam, Philippines, Malaysia, Myanmar, United Arab Emirates, and Venezuela. Sinopharm is also working on updated vaccines to address the Beta and Delta variants.

In June 2021, the WHO approved for emergency use the vaccine known as CoronaVac, developed by Sinovac Biotech Ltd - a Nasdaq-listed company under the state-owned China National Pharmaceutical Group. As of August 2021, Sinovac had produced nearly 1.3 billion doses which can be distributed across Bolivia, China, Indonesia, Turkey, Brazil, Chile, Colombia, Mexico, Cambodia, Hong Kong, Thailand, Tunisia, Ukraine, Pakistan, Malaysia, Egypt, Bangladesh, Nepal, South Africa, and Sri Lanka. Although Sinovac has not joined C-TAP, it has signed contracts that include technology transfer with other countries such as Brazil and Indonesia.

Operating under the Russian Ministry of Health since 2020 and financed by the Russian Direct Investment Fund (RDIF), the Gamaleya National Research Center of Epidemiology and Microbiology developed the two-dose vaccine Gam-COVID-Vac, also known as Sputnik V.
V. In August 2020, the Russian Ministry of Health approved the use of Sputnik V. One year later, the Gameleya Center has produced 14 million doses of the vaccine worldwide. While over 70 national public health regulatory bodies have approved Sputnik, the WHO still has not approved its use and therefore it has yet to be used by COVAX. The Gameleya Center is also working on a one-dose vaccine called Sputnik-light, which is also pending approval from the WHO and the European Medicines Agency (EMA). The Gamaleya and RDIF have not joined C-TAP, but they have signed contracts with local manufacturers in several countries, including Bangladesh, India, Iran and Mexico.

Despite claims of lack of transparency around the safety of the vaccine, as of August 2021, Sputnik V has been approved for emergency use in nearly 60 countries and territories.

CONCLUSION

As this assessment has shown, while vaccine developers claim to respect human rights, all of them – to differing degrees – have failed to meet their responsibilities. Through their actions and omissions – particularly through their inaction on intellectual property and technology sharing – these companies have ended up causing or contributing to the human rights harms suffered by those lacking access to the Covid-19 vaccine. Despite billions of dollars of public subsidy, they have catered predominantly to rich countries, leaving poor countries at the back of the queue.

All of the pharmaceutical companies assessed have actively opposed efforts to increase sharing of intellectual property, technology and knowhow beyond limited numbers of bilateral agreements. Johnson & Johnson has refused to share its intellectual property, technology and knowhow even when explicitly requested to do so by a company seeking to increase access to Covid-19 vaccines in the Global South.

No company has yet joined WHO initiatives, such as C-TAP and the mRNA vaccine technology transfer hub designed to scale up global manufacturing. No company has publicly disclosed disaggregated costs of research, development, production, marketing, distribution, and other data crucial for optimizing the vaccine production and allocation.

AstraZeneca and Johnson & Johnson state that they are committed to producing on a not-for-profit basis for emergency pandemic use. In contrast, Pfizer/BioNTech and Moderna have charged high prices for their vaccines, putting profits before access to essential medicines. Pfizer/BioNTech and Moderna have also allocated almost all of vaccines so far delivered (as opposed to pledged) to high-income countries. Apart from AstraZeneca, all companies have been slow to deliver doses into the COVAX Facility, meaning that the majority of doses currently pledged will only be delivered in 2022 – very late for many poorer regions now suffering deadly Covid-19 outbreaks. If Novavax is able to follow through on its significant commitments to supply COVAX, this would be a major boost to the scheme and support fair access to essential medicines.

AstraZeneca should be recognized for its approach to the crisis. However, the scale of the global health emergency requires much greater action from all of the vaccine producers, including AstraZeneca itself, which has also obstructed broader measures to share intellectual property, technology and knowhow.

324 Sputnik V, “Partnerships”, sputnikvaccine.com/partnerships/
327 Sputnik V, “Newsroom”, sputnikvaccine.com/newsroom/
329 These include Albania, Azerbaijan, Hungary, Kazakhstan, Montenegro, Russia, Saint Vincent and the Grenadines, Serbia, Syria and Uzbekistan.
## 4. The Top Ten Institutional Investors

Each of the companies featured in this report is publicly listed, and therefore owned by numerous individual and institutional investors. But among these, a small group of mainly US-based mega investors and financial service institutions own or manage a significant shareholding across the industry.

For this report, Amnesty International has mapped the ten largest institutional investors who own or manage shares of the six featured companies, as per Bloomberg listings. The total investments owned or managed by these ten financial institutions in the vaccine makers are huge – more than US$250 billion.

The single largest is Vanguard Group Inc. This group holds shares worth a total of more than US$66 billion, in AstraZeneca, Johnson & Johnson, Moderna, Novavax and Pfizer. BlackRock Inc has more than US$62 billion invested in all six featured companies. State Street Corporation has more than US$36 billion invested in all companies assessed except for BioNTech.

### The Human Rights Responsibility of Investors

As outlined above, under the UN Guiding Principles, business enterprises, have a responsibility to respect all human rights wherever they operate in the world and throughout their operations. This responsibility to respect applies not just to the vaccine manufacturers but also to the companies that invest in them, including institutional investors.

### Table: The Top Ten Institutional Investors

<table>
<thead>
<tr>
<th>#</th>
<th>Investor</th>
<th>Country</th>
<th>Total Shares Owned</th>
<th>Value of Holding in USD (as of 26.05)</th>
<th>%</th>
<th>% of total shares</th>
<th>% of value of holding in USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Vanguard Group Inc</td>
<td>USA</td>
<td>4,265,000,000</td>
<td>9,088,348,200</td>
<td>5.3%</td>
<td>21.6%</td>
<td>26.6%</td>
</tr>
<tr>
<td>2</td>
<td>BlackRock Inc</td>
<td>USA</td>
<td>5,388,747,100</td>
<td>10,701,148,600</td>
<td>5.2%</td>
<td>26.9%</td>
<td>26.9%</td>
</tr>
<tr>
<td>3</td>
<td>State Street Corp</td>
<td>USA</td>
<td>3,294,833,400</td>
<td>8,248,569,200</td>
<td>7.6%</td>
<td>41.6%</td>
<td>62.3%</td>
</tr>
<tr>
<td>4</td>
<td>Capital Group Co Inc</td>
<td>USA</td>
<td>2,637,146,600</td>
<td>6,855,504,000</td>
<td>2.0%</td>
<td>16.0%</td>
<td>25.1%</td>
</tr>
<tr>
<td>5</td>
<td>Morgan Stanley</td>
<td>USA</td>
<td>2,17,946,000,000</td>
<td>463,120,28</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>6</td>
<td>Baillie Gifford</td>
<td>Switzerland</td>
<td>1,357,056,000</td>
<td>3,874,553,700</td>
<td>0.9%</td>
<td>2.0%</td>
<td>11.9%</td>
</tr>
<tr>
<td>7</td>
<td>Bank of New York Mellon</td>
<td>USA</td>
<td>1,089,284,100</td>
<td>3,544,212,000</td>
<td>0.7%</td>
<td>5.6%</td>
<td>10.0%</td>
</tr>
<tr>
<td>8</td>
<td>Envestnet</td>
<td>USA</td>
<td>249,022,93</td>
<td>5,611,922,600</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>9</td>
<td>State Street Corporation</td>
<td>USA</td>
<td>950,221,300</td>
<td>2,361,017,800</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>10</td>
<td>UBS</td>
<td>Switzerland</td>
<td>23,737,208,300</td>
<td>62,674,079,100</td>
<td>11.2%</td>
<td>32.8%</td>
<td>25.7%</td>
</tr>
</tbody>
</table>

### Sources

330 Mapping based on data from Bloomberg Terminal, as accessed on 26 May 2021.
331 Vanguard, Investors, investor.vanguard.com/corporate-portal/
332 BlackRock, www.blackrock.com
334 Scope and applications of “business relationships” in the financial sector under the OECD Guidelines for Multinational Enterprises, rneguidelines.oecd.org/global-forum/GFRBC-2014-financial-sector-document-2.pdf, According to the OECD, “It is interpretive guidance regarding the applicability of the UNGPs by minority shareholders, the OHCHR therefore concludes that (minority) shareholdings of institutional investors constitute a business relationship.” See also UNGPs 10+ and UN B-Tech dialogue on investment and human rights, OHCHR B-Tech, 2020, www.ohchr.org/Documents/Issues/Business/UNGPsBHReNext10/ConceptNoteUNGPs10_BTech.pdf, which clarifies that “[t]he term institutional investor’s refers to institutions invested in public equities, fixed income, and private equities, including venture capital funds.”
To meet their responsibility to respect under the UN Guiding Principles, investors in pharmaceutical companies must undertake proactive and ongoing human rights due diligence.\textsuperscript{335}

In practice, this would entail identifying human rights impacts linked to their operations and investments (both potential and actual), taking effective action to prevent and mitigate against them, and being transparent about their efforts.\textsuperscript{336}

For investors, this applies to their decisions about which companies to invest in as well as the sectors on which to focus. Investors must undertake human rights due diligence to assess the potential or actual human rights impacts of the companies they choose to support through financial investments – i.e. the potential or actual impacts of those companies’ actions and products. They should also continue to monitor their portfolio companies to identify any new or emerging human rights risks.\textsuperscript{337} This equally applies to financial service institutions managing assets owned by others.\textsuperscript{,}

Once an investor has identified potential or actual adverse impacts, they should engage with their investee company and exert their leverage to mitigate these adverse impacts.\textsuperscript{338} They should also insist that their investees conduct their own human rights due diligence.\textsuperscript{339}

In the context of the Covid-19 vaccines the leverage that this small group of companies has is significant.\textsuperscript{340} While none of the top ten investors own more than 10\% in any one company, the size of their combined holdings, as well as their total portfolios across the whole sector, give them a significant role in these companies. Combined, for instance, they own 22.7\% of AstraZeneca’s shares, 27.9\% of Johnson & Johnson’s, 24.6\% of Moderna’s, 17.3\% of Novavax’s, and 32.7\% of Pfizer’s.\textsuperscript{341}

Within the context of the pandemic, some investors have recognized, at least partially, their responsibility to try to influence the vaccine makers to take all necessary steps to extend access to Covid-19 vaccines. Almost 150 institutional investors joined a public call in February 2021 for pharmaceutical companies to support “a fair and equitable global response to the pandemic” through, for example, “cross-industry partnerships to accelerate R&D and expand production, equitable pricing strategies, and voluntary licensing agreements”.\textsuperscript{342}

Responding to Amnesty International’s inquiries about their due diligence in relation to the vaccine developers assessed, Baillie Gifford stated “We identified that global access to vaccines would be a major human rights risk given that ground-breaking innovation in healthcare is primarily taking place in high income countries. Therefore […] we engaged with Moderna and BioNTech early on and during the pandemic to discuss what they would do to support global vaccine rollout.”\textsuperscript{343} BlackRock said that it engages with pharmaceutical companies “on all aspects of their business” including “asking questions to understand their role in Covid-19 vaccines”. The company added that “access to medicine is a key ESG concern held by BlackRock”.\textsuperscript{344} UBS wrote that it sees pharmaceutical companies as having “an important role to play in addressing the access to medicine issue” and that it “engage[s] with pharmaceutical companies to directly address the issue of access to medicine and human rights”.\textsuperscript{345} However, neither Baillie Gifford, BlackRock, UBS or any of the other top ten institutional investors, as identified by Amnesty International, were among the signatories of the public call by almost 150 investors in February 2021.

\textsuperscript{335} Publicly available information on the human rights commitments of the top ten institutional investors in the six featured companies can be found in Annex 1.
\textsuperscript{336} UN Guiding Principles, Principles 15 and 17.
\textsuperscript{337} OECD, “Responsible business conduct for institutional investors: Key considerations for due diligence under the OECD Guidelines for Multinational Enterprises”, p. 33, mneguidelines.oecd.org/RBC-for-Institutional-Investors.pdf.
\textsuperscript{338} OECD, “Responsible business conduct for institutional investors: Key considerations for due diligence under the OECD Guidelines for Multinational Enterprises”, p. 35, mneguidelines.oecd.org/RBC-for-Institutional-Investors.pdf.
\textsuperscript{339} OECD, “Responsible business conduct for institutional investors: Key considerations for due diligence under the OECD Guidelines for Multinational Enterprises”, p. 35, mneguidelines.oecd.org/RBC-for-Institutional-Investors.pdf.
\textsuperscript{340} While some investors may not have operational control over their investee companies, the responsibility to try to prevent and mitigate adverse human rights impacts applies to all investors that invest in a company. According to the OECD, “The degree of leverage an investor has over the company causing the adverse impact is useful in considering what it can do to persuade that entity to take action, but is not relevant to considering whether the investor should carry out due diligence and effectively exercise any leverage it may have.” OECD, “Responsible business conduct for institutional investors: Key considerations for due diligence under the OECD Guidelines for Multinational Enterprises”, p. 38, mneguidelines.oecd.org/RBC-for-Institutional-Investors.pdf.
\textsuperscript{341} Of the top ten investors overall, only three own shares in Biontech, which are worth just 3.4\% of the total shares in the company. Mapping based on data from Bloomberg Terminal, accessed 26 May 2021.
\textsuperscript{343} Baillie Gifford & Co, Letter to Amnesty International, 10 September 2021, on file.
\textsuperscript{345} UBS, Email to Amnesty International, 10 September 2021, on file.
5. CONCLUSIONS AND RECOMMENDATIONS

“A global pandemic of this scale and human cost, with no clear end in sight, requires a concerted, principled and courageous response […] based on the bedrock human-rights based principles of international solidarity, cooperation and assistance.” UN Human Rights Experts, 9 November 2020

The current structure of the global public health system affords private actors a fundamental role in the development, manufacturing, and allocation of medicines. The protection of international intellectual property rights puts manufacturers of medicines in a position of immense power which allows them to decide whether and under what conditions other companies and countries can develop and manufacture life-saving Covid-19 vaccines. Vaccine developers – many extraordinarily profitable – must exercise that power in alignment with their human rights responsibilities.

Some pharmaceutical companies are putting profits first. They cannot continue to adopt a business-as-usual approach during a global health emergency when the health and lives of millions are at stake. Their approach – notwithstanding commitments by AstraZeneca and Johnson & Johnson to sell at cost price during the pandemic - has ultimately failed to address the global health crisis, and resulted in the concentration of intellectual property, knowledge, technology, profit and vaccines in the Global North, whilst the Covid-19 crisis worsens for the Global South.

Companies must not enforce existing intellectual property rights, and refrain from applying and enforcing new intellectual property rights. They must issue global, open and non-exclusive licences on their patents, know-how and other proprietary technologies or participate in C-TAP. They must share and fully transfer their knowledge and technology and train qualified manufacturers committed to contribute to the ramp-up of the production of Covid-19 vaccines. They should not seek to use their influence over governments to obstruct measures designed to facilitate intellectual property and technology sharing, such as the proposed TRIPS Waiver. With regards to pricing, companies must not put their economic interests before their human rights responsibilities; profit must not become an obstacle to states’ capacity to ensure access to the vaccine. All companies must prioritize increasing availability of vaccines in poorer regions and countries by devoting a significant share of their 2021 production to the COVAX Facility and sustaining high levels of deliveries into COVAX throughout 2022. Transparency across all aspects of vaccine development and delivery is vital for optimizing supply and ensuring fair vaccine allocation.

In the long run, solely market-driven models will never deliver essential medicines fairly. Stronger laws and regulations – especially around accessibility and affordability – are needed for states and companies to deliver on their respective human rights obligations and responsibilities. States must ensure that intellectual property rights do not prevent any countries from upholding the right to health. This includes agreeing to a ‘waiver’ on certain aspects of the TRIPS agreement for the production of Covid-19 health products, supporting the WHO’s COVID-19 Technology Access Pool (C-TAP), and placing conditions on public funding to ensure pharmaceutical companies share their innovations, technology, and data with other manufacturers. States must also assess and make any necessary adjustments to their intellectual property laws, policies, and practices to ensure that these do not form a barrier to access to health.

In July, a task force set up by the leaders of the WHO, WTO, IMF and World Bank set a target to vaccinate 40% of people in low and lower-middle income countries by the end of 2021, to protect them and others from Covid-19. With 100 days until the end of the year, less than 10% of people in these countries are fully vaccinated, and tens of thousands of people are dying each week.

As the world reaches a critical phase of the pandemic, Amnesty International is launching a campaign calling on states and pharmaceutical companies to deliver 2 billion vaccines to 82 low and lower-middle income countries over the next 100 days, in order to fully vaccinate an additional 1.2 billion. To reach this goal, companies and states need to adopt a radically different approach to vaccine allocation: companies must distribute 50% of their production to low- and lower-middle income countries, preferably through the COVAX Facility and other multilateral initiatives; states must urgently redistribute hundreds of millions of surplus vaccines currently in their stocks, favouring international and regional mechanisms such as COVAX. These measures alone could bridge the gap.

The challenge must not stop there. States and companies must ensure that deliveries continue to be equitable throughout 2022, that doses go where they are most needed and that low and lower-middle income countries are fully vaccinated as quickly as possible. Action must also be taken to share the knowledge, technology and intellectual property needed to allow more manufacturers to produce vaccines, and facilitate equitable access to affordable vaccines for years to come.

RECOMMENDATIONS

Amnesty International is calling on vaccine developers to:

- Deliver 50% of their production of Covid-19 vaccines to low- and lower-middle income countries throughout the last 100 days of 2021, preferably through international and regional mechanisms such as COVAX, and ensure that deliveries continue to be equitable throughout 2022 and beyond.
- Carry out human rights due diligence to identify, prevent, mitigate and account for how they address potential and actual adverse human rights impacts in relation to their Covid-19 vaccines.
- Pursue vaccine allocation based on human rights considerations, such as the prevalence of the pandemic in a country, the functioning of a country’s health care system, vaccination rate and non-discrimination. To ensure this, commit a significant share of their annual production to the COVAX Facility, including state donations.
- Engage with the purchasers of their Covid-19 vaccines and build in contractual flexibility regarding delivery terms to ensure that those most at risk globally get access to the vaccines in a timely manner, especially in cases of sudden Covid-19 outbreaks which require urgent responses.
- Share intellectual property by issuing open and non-exclusive licences or participating in C-TAP, and publicly disclosing all terms and conditions.
- Share their codified and tacit knowledge and technology and train qualified manufacturers committed to contribute to the ramp-up and diversification of the production of Covid-19 vaccines by participating in C-TAP and, where applicable, making use of technology transfer hubs established by the WHO.
- Price their vaccine doses so that profit does not constitute an obstacle to access to Covid-19 vaccines. At a minimum, supply vaccines at cost to low- and middle-income countries for at least the duration of the global health emergency.
- Publicly disclose their pricing and allocation policies in a timely and accessible fashion, including the actual costs of production, individual cost items, sources of external funding, prices charged in different countries under what contractual terms and conditions, and information about discounting, donations and advance order guarantees.
- Allow purchasing states to sell or donate any surplus of Covid-19 vaccine doses to other countries, including for donation via NGOs or the WHO, without a prior consent of the vaccine developer or any other obstacle such as indemnity clauses.
- Respect the spirit of the Doha Declaration on the TRIPS Agreement and Public Health (2001) by not opposing initiatives that increase access to Covid-19 health products, such as the proposed waiver to WTO TRIPS Agreement.
- Cease lobbying against initiatives seeking to increase manufacture and supply of Covid-19 vaccines and promote their fair distribution, such as the proposed TRIPS waiver and WHO technology sharing mechanisms.
- Engage in remediation of human rights harm in all instances in which they have caused, contributed to or are directly linked to the harm.
Amnesty International is calling on institutional investors owning or managing shares of vaccine developers to:

- conduct comprehensive human rights due diligence on their investments and financial services. This includes:
  
  a. Monitoring the human rights implications of the vaccine developers’ Covid-19 vaccines on an ongoing basis, and taking immediate action to prevent any adverse impacts, mitigate any risks and remedy any harm that they identify.
  
  b. Publicly disclosing the human rights due diligence they conduct and actions taken to prevent and remediate any harm and mitigate any risk in relation to the vaccine developers’ Covid-19 vaccines.
  
  c. Requiring publicly accessible annual reporting from the vaccine developers whose shares they hold or manage on their human rights due diligence, including accounting for how they are addressing or have addressed any adverse human rights impact in relation to their Covid-19 vaccines.
  
  d. Ensuring that the vaccine developers whose shares they hold or manage implement their own due diligence process to identify, prevent, mitigate and account for the actual and potential human rights impacts linked to the development, production, trade and allocation of their Covid-19 vaccines.

And states to:

- Redistribute all surplus Covid-19 vaccine stocks to low- and lower-middle income countries over the last 100 days of 2021, preferably through international and regional mechanisms such as COVAX, and ensure that vaccine allocation continues to be equitable throughout 2022 and beyond.
  
- Put measures in place, including legislation, to prevent vaccine developers from impeding access to Covid-19 vaccines.
  
- Support and resource C-TAP and promote open and non-exclusive licences that include knowledge and technology transfer.
  
- Source Covid-19 vaccines through COVAX to allow fair vaccine allocation based on human rights considerations such as non-discrimination, prevalence of the pandemic in a country, the functioning of a country’s health care system, and a country’s vaccination rate.
  
- Put all necessary measures in place, and support countries in need, to ensure effective and fair vaccination roll-out upon receipt of vaccine doses.
  
- Respect the spirit of the Doha Declaration on the TRIPS Agreement and Public Health (2001) by supporting initiatives that increase access to Covid-19 health products, such as the waiver to WTO TRIPS Agreement and making use of the TRIPS flexibilities in a timely fashion.
  
- Make public funding for companies transparent and conditional on companies sharing intellectual property, knowledge and technology, joining global vaccine supply and technology sharing mechanisms, such as C-TAP, and publicly disclosing disaggregated costs of research, development, production, marketing, distribution, and all other relevant data in a timely and accessible fashion.
  
- Allow contractual flexibility for vaccine developers regarding delivery terms to ensure that those most at risk globally get access to the vaccines in a timely manner, in particular where sudden Covid-19 outbreaks require urgent responses.
  
- Publicly disclose terms and conditions of agreements with vaccines developers, including funding, advance purchasing, and purchasing agreements.
  
- Support efforts to reform intellectual property rights regimes to ensure universal access to essential, life-saving medicines.
ANNEX 1: HUMAN RIGHTS COMMITMENTS OF THE TOP TEN INSTITUTIONAL INVESTORS

Each of the top ten institutional investors has committed publicly to respecting human rights, while some have also made an explicit reference to the UN Guiding Principles and the requirement to conduct human rights due diligence, and where necessary engage with their investee companies. However, the scale of this commitment varies, with only small numbers explicitly referring to their engagement with companies whose shares they own or manage in relation to human rights concerns.

Vanguard Group Inc has stated that it established a “formal procedure to identify and monitor portfolio companies whose direct involvement in crimes against humanity or patterns of egregious abuses of human rights would warrant engagement or potential divestment.” Though information on the procedure is limited, the procedure seems not to align with the UN Guiding Principles, which require business enterprises to address any human rights risks, not only those amounting to crimes against humanity or reflecting patterns of egregious human rights abuses. Further, measures to mitigate risks and prevent harm can be manifold and are not limited to divestment. They for instance include exerting leverage over the investee to ensure human rights compliance.

BlackRock Inc has a detailed human rights policy that explicitly refers to the UN Guiding Principles and the OECD. It states that it asks the companies that it invests in to “implement processes to identify, manage, and prevent adverse human rights impacts that are material to their business, and provide robust disclosures on these practices.” While this commitment to request human rights due diligence from investees, it does not fully align with the UN Guiding Principles which require companies to address any human rights risks, not only those which are material to the business. BlackRock also states its commitment to “engaging with companies on how they manage the human rights issues that are inherent in their businesses and monitor human rights practices on a best-efforts basis.”

State Street Corporation states that it is committed to “fair, ethical and responsible business practices” and that it “supports fundamental principles of human rights, such as those adopted in the United Nations Universal Declaration of Human Rights”. But its statement on human rights does not reference the UN Guiding Principles or provide any information about whether or how it engages with investees in relation to human rights risks.

Capital Group Cos Inc acknowledges the Universal Declaration of Human Rights and other international human rights standards and believes that “it is an essential obligation of our portfolio holdings to uphold these fundamental standards in their own operations and throughout their supply chains”. The investor further expects organisations to “conduct due diligence and monitoring of their supply chain.” Its human rights statement does not reference the UN Guiding Principles but does state that the company has “systematically incorporated” human rights into its investment processes. The company adds that “in our firmwide ESG monitoring and engagement programs, we seek to ensure that analysts are aware of potential violations and engaging with issuers on these topics.”

Wellington Management Group LLP does not have a human rights policy. It invites investees to work on their environmental, social and governance performance with the view for investees to “[r]educe the risk of being a target of shareholder activism.” In the “Adverse Sustainability Impacts Statement” of the Wellington Management Europe GmbH ("WME"), a member of Wellington Management, under the European Sustainable Finance Disclosure Regulation, WME states that Wellington Management will identify companies which have business practices which breaches any one of the ten Global Compact Principles. These include a commitment to “support and respect the protection of internationally proclaimed human rights” and to “make sure that they are not complicit in human rights abuses”. In its 2020 Sustainability Report Wellington Management Group says it supports the UN Sustainable Development Goals, and says it is committed to “sustainable investing”. This includes a commitment to “engaging with companies to understand their strategy, financial and nonfinancial performance and risk, capital structure, social and environmental impact, and corporate governance and seek to guide and encourage change where appropriate.”

437 Vanguard, Principles and Policies, about.vanguard.com/investment-stewardship/principles-policies/
441 Wellington Management, “ESG insights for private companies”, ESG insights for private companies — The critical role of ESG in private equity - US - Wellington Management
Baillie Gifford has a clear policy on human rights, stating that it expects “all our holdings to respect internationally accepted human rights and labour rights throughout their business operations and value chain in line with the United Nations Guiding Principles for Business and Human Rights.” It does not explain further how it implements this commitment in its due diligence processes.

Bank of America Corp has a human rights statement in which the company commits to promote and protect human rights, and to conduct its business in a manner consistent with the Universal Declaration of Human Rights, the UN Guiding Principles on Business and Human Rights and the International Labor Organization’s Fundamental Conventions. It does not further elaborate how this commitment is operationalised in its due diligence processes.

Morgan Stanley states that it acknowledges “the corporate responsibility to respect human rights articulated in the United Nations’ Guiding Principles on Business and Human Rights”. It also states that “[h]uman rights considerations are incorporated into our transaction due diligence process, our engagement with companies, our supplier expectations, and our own operations.” And that “[a]reas of potential heightened human rights risk undergo enhanced diligence and may be escalated to senior management.

Bank of New York Mellon states that it is “committed to the protection and preservation of human rights around the world” and that it applies “these principles to everyone we do business with inclusive of our employees, suppliers, clients, communities and other stakeholders.” The bank’s human rights statement does not, however, reference the UN Guiding Principles or other standards or detail further how it operationalises its commitment, in particular in its due diligence processes.

UBS has also issued a human rights statement which makes references the UN Guiding Principles. USB states that it has put a process in place which “helps us identify and manage potential adverse impacts to the environment and to human rights”. Further, the company is committed “to reporting on the focus areas of this statement.”

---


Dear Mr. Wilcken,

Thank you very much for your recent correspondence in relation to AstraZeneca’s human rights responsibilities regarding access to health. We have a proud record in these areas and are pleased to be able to respond.

I can personally assure you that we take our commitment to global public health and corresponding human rights responsibilities extremely seriously. From the outset of the pandemic, we knew we had a responsibility to act given our capacity to make a real difference to people’s lives and health. That is why, as indicated in your letter, we are committed to supplying our COVID-19 vaccine broadly and equitably at no profit during the pandemic in response to a global public health emergency. Our aim is to meet an urgent need and support healthcare systems and economies to recover. It is through this that we hope to improve the lives and health of people globally, an objective that is underpinned by our commitment to human rights.

Our firm belief is that no one is safe until we are all safe, and this is why AstraZeneca has supplied its vaccine to over 170 countries globally to date. We were also the first vaccine manufacturer to partner with COVAX, the multilateral global equitable access initiative, so far providing 96 percent of the 70m+ doses supplied to over 120 countries – the majority of which are low- and middle-income countries. We work closely with CEPI, GAVI, the World Health Organization and others to maximise distribution and equitable vaccine access.

Intellectual Property (IP) and Technology Transfer
IP is the key driver of innovation for the research-based pharmaceutical industry, which has enabled unprecedented collaboration between industry and governments to develop life-saving medicines, including to speed up progress on COVID-19 vaccines and treatments.

Building on our experience as a leading COVID-19 vaccine manufacturer, we believe the most effective way to address the pandemic is for vaccine manufacturers with specialised expertise to support the timely transfer of technological capabilities and know-how where production can be set up or ramped up at scale, combined with a commitment to supply billions of doses at not-for-profit pricing. We see this approach as supporting increased global access.

For AstraZeneca, an IP waiver would be unlikely to increase our global vaccine production as a significant proportion of our supply chain is already in the geographic regions supposed to benefit from this change.

We are open to exploring viable options to further expand the production of our vaccine while we optimise the productivity of existing supply, as part of our ambition to provide our COVID-19 vaccine to people around the world and help end the pandemic.

Licensing Agreements and Due Diligence
AstraZeneca has risen to the challenge of creating a vaccine that is widely available around the world, so far securing supply capacity for billions of doses of the vaccine. In just one year, we have built a global supply network with more than a dozen parallel supply chains and more than 20 partners over 15 countries to deliver on our commitment to broad, timely and equitable access and accelerate vaccine production.

In building our supply chains, we have shared IP and know-how with capable and established vaccine manufacturing organisations to scale up supply. We have signed four sublicensing agreements, with those organisations managing the allocation of their vaccine supply. This includes partnerships in low- and middle-income countries, such as the Serum Institute in India (SII), through which we have supplied 90% of the COVID-19 vaccines in India. Our approach has been to leverage local manufacturing where possible to balance speed of supply against our no profit pledge, while upholding the highest quality standards.

Pricing Policy and COVISHIELD™
At the start of the pandemic we made a commitment to make the vaccine available to as many countries as possible at no profit to support broad and equitable access around the world. However, given the complexity of global supply chains, cost of the vaccine can vary depending on supply chain, location and volumes requested by countries. This explains price differentiations between different countries. In addition to the manufacturing costs, AstraZeneca is incurring costs globally that include clinical development, regulatory, distribution, pharmacovigilance and other expenses.

COVISHIELD™ (manufactured by SII) and COVID-19 Vaccine AstraZeneca (manufactured by AstraZeneca) are the same vaccine developed by University of Oxford. COVISHIELD™ is priced according to our global no profit commitment, as is the case across our entire supply network, with local variables dictating cost.

As you will appreciate, our entire focus right now is on playing our part in ending the current pandemic and helping in our shared objective of vaccinating the world. We are not yet in a position to be discussing any plans in relation to future agreements.

We hope this information gives you a strong sense of our deep commitment to equitable vaccine distribution, protection of ethics and human rights as part of our shared public health responsibility. As always, we will be guided by our core values as a healthcare leader on what we believe is the right thing to do.

I want to thank you for your engagement and leadership in ensuring human rights accountability throughout the pharmaceutical industry at such a critical time. There has never been a more important time to ensure global accountability and widespread commitment to the sanctity of human rights. We strive to improve the lives of people all over the world, and are pleased to have an opportunity to play our part to support global recovery.

We hope this can be part of an ongoing dialogue as we work towards our shared ambitions on these important areas.

Yours sincerely,

I can personally assure you that we take our commitment to global public health and corresponding human rights responsibilities extremely seriously. From the outset of the pandemic, we knew we had a responsibility to act given our capacity to make a real difference to people’s lives and health. That is why, as indicated in your letter, we are committed to supplying our COVID-19 vaccine broadly and equitably at no profit during the pandemic in response to a global public health emergency. Our aim is to meet an urgent need and support healthcare systems and economies to recover. It is through this that we hope to improve the lives and health of people globally, an objective that is underpinned by our commitment to human rights.

Our firm belief is that no one is safe until we are all safe, and this is why AstraZeneca has supplied its vaccine to over 170 countries globally to date. We were also the first vaccine manufacturer to partner with COVAX, the multilateral global equitable access initiative, so far providing 96 percent of the 70m+ doses supplied to over 120 countries – the majority of which are low- and middle-income countries. We work closely with CEPI, GAVI, the World Health Organization and others to maximise distribution and equitable vaccine access.

Intellectual Property (IP) and Technology Transfer
IP is the key driver of innovation for the research-based pharmaceutical industry, which has enabled unprecedented collaboration between industry and governments to develop life-saving medicines, including to speed up progress on COVID-19 vaccines and treatments.

Building on our experience as a leading COVID-19 vaccine manufacturer, we believe the most effective way to address the pandemic is for vaccine manufacturers with specialised expertise to support the timely transfer of technological capabilities and know-how where production can be set up or ramped up at scale, combined with a commitment to supply billions of doses at not-for-profit pricing. We see this approach as supporting increased global access.

For AstraZeneca, an IP waiver would be unlikely to increase our global vaccine production as a significant proportion of our supply chain is already in the geographic regions supposed to benefit from this change.

We are open to exploring viable options to further expand the production of our vaccine while we optimise the productivity of existing supply, as part of our ambition to provide our COVID-19 vaccine to people around the world and help end the pandemic.

Licensing Agreements and Due Diligence
AstraZeneca has risen to the challenge of creating a vaccine that is widely available around the world, so far securing supply capacity for billions of doses of the vaccine. In just one year, we have built a global supply network with more than a dozen parallel supply chains and more than 20 partners over 15 countries to deliver on our commitment to broad, timely and equitable access and accelerate vaccine production.

In building our supply chains, we have shared IP and know-how with capable and established vaccine manufacturing organisations to scale up supply. We have signed four sublicensing agreements, with those organisations managing the allocation of their vaccine supply. This includes partnerships in low- and middle-income countries, such as the Serum Institute in India (SII), through which we have supplied 90% of the COVID-19 vaccines in India. Our approach has been to leverage local manufacturing where possible to balance speed of supply against our no profit pledge, while upholding the highest quality standards.

Pricing Policy and COVISHIELD™
At the start of the pandemic we made a commitment to make the vaccine available to as many countries as possible at no profit to support broad and equitable access around the world. However, given the complexity of global supply chains, cost of the vaccine can vary depending on supply chain, location and volumes requested by countries. This explains price differentiations between different countries. In addition to the manufacturing costs, AstraZeneca is incurring costs globally that include clinical development, regulatory, distribution, pharmacovigilance and other expenses.

COVISHIELD™ (manufactured by SII) and COVID-19 Vaccine AstraZeneca (manufactured by AstraZeneca) are the same vaccine developed by University of Oxford. COVISHIELD™ is priced according to our global no profit commitment, as is the case across our entire supply network, with local variables dictating cost.

As you will appreciate, our entire focus right now is on playing our part in ending the current pandemic and helping in our shared objective of vaccinating the world. We are not yet in a position to be discussing any plans in relation to future agreements.

We hope this information gives you a strong sense of our deep commitment to equitable vaccine distribution, protection of ethics and human rights as part of our shared public health responsibility. As always, we will be guided by our core values as a healthcare leader on what we believe is the right thing to do.

I want to thank you for your engagement and leadership in ensuring human rights accountability throughout the pharmaceutical industry at such a critical time. There has never been a more important time to ensure global accountability and widespread commitment to the sanctity of human rights. We strive to improve the lives of people all over the world, and are pleased to have an opportunity to play our part to support global recovery.

We hope this can be part of an ongoing dialogue as we work towards our shared ambitions on these important areas.

Yours sincerely,
Statement on Amnesty International publication on vaccine developers’ human rights responsibilities in relation to the Covid-19 vaccine rollout

As a COVID-19 vaccine manufacturer we see it as our responsibility to support the worldwide supply of the Pfizer/BioNTech vaccine by continuously increasing our manufacturing capacities. We recognize and agree with the need for supply of vaccine doses to low and lower-middle income countries. To date, Pfizer and BioNTech have shipped more than 1.4 billion COVID-19 vaccine doses to more than 100 countries or territories in every region of the world. The companies are firmly committed to working towards equitable and affordable access for COVID-19 vaccines for all people around the world, actively working with global governments as well as global health partners with the aim to provide 2 billion doses to low- and middle-income countries in 2021 and 2022 – 1 billion each year. This includes an agreement to supply 500 million doses to the U.S. Government at a not-for-profit price, that the government will, in turn, donate to the African Union and the COVAX 92 Advanced Market Commitment (AMC) countries, as well as a direct supply agreement with the COVAX facility for 40 million doses. We are fully committed to supplying our vaccine to people around the world in all countries and across all income levels. We all know that no one will be safe until everyone is safe.

However, patents are not the limiting factor for the production or supply of our vaccine. They would not increase the global production and supply of vaccine doses in the short and middle term. Experts have already pointed out, that the set-up and validation of new manufacturing sites usually takes up to one year. Furthermore, there are many important factors separate from patent considerations that are involved in producing an mRNA vaccine to ensure its quality, safety and efficacy. The manufacturing process of mRNA is a complex process developed over more than a decade. All steps must be precisely defined and executed accurately. It takes experienced personnel. It takes raw materials that need to be sourced and qualified for use. It takes established processes for preparing the vaccine which need to be followed meticulously. If any of these requirements is not met, the quality, safety and efficacy of the vaccine cannot be ensured by the manufacturer nor the innovator. This could put the health of the vaccinees at risk. Also, there is the risk that some of the limited and important raw materials are not used in an efficient manner thereby reducing the amount of vaccines doses that can be produced in already established manufacturing networks.

We have conducted numerous technology transfers to dramatically increase production of our vaccine while ensuring the highest quality standards. This is why we are already working closely with partners under licensing and manufacturing agreements to further establish a global GMP-certified manufacturing network which meets all requirements to manufacture safe and effective vaccines. Together with Pfizer, we have entered into additional contracts with more than 150 vendors specifically supporting the development and production of our vaccine. We also plan to incorporate Biovac’s Cape Town (SA) facility for fill & finish into the vaccine supply chain by the end of 2021 to support supply on the african continent. We have also signed a letter of intent with Brazilian biopharmaceutical company Eurofarma Laboratórios to perform manufacturing activities within Pfizer’s and BioNTech’s global COVID-19 vaccine supply chain and manufacturing network for distribution within Latin America. Pfizer’s and BioNTech’s global COVID-19 vaccine supply chain and manufacturing network, which will now span four continents and include more than 20 manufacturing facilities. BioNTech has already started the evaluation of manufacturing capabilities, following the Company’s announcement of its aim to develop a well-tolerated and highly effective Malaria vaccine and to implement sustainable end-to-end vaccine supply solutions on the African continent. The decision to evaluate manufacturing solutions in Rwanda and Senegal follows the guidance of the African Union, the Africa Centres for Disease Control and Prevention (Africa CDC) and the African Medical Agency under formation. The prospective locations of the necessary manufacturing sites are expected to co-locate with the World Health Organization’s (WHO) upcoming Vaccine Hubs. These efforts will be aligned with the Team Europe Initiative on manufacturing and access to vaccines, medicines and medical technologies (MAV+) led by the European Commission in collaboration with the EU Member States.

We believe that the continued expansion of manufacturing capabilities leveraging GMP-certified sites and experienced manufacturers will help to end this pandemic by ensuring worldwide supply with safe and effective vaccines. In order to achieve this, governments, manufacturers as well as international and national organizations will have to jointly support the supply of low and lower middle income countries from the already existing manufacturing sites and help to identify new certified sites. This applies for manufacturing capacities and supply agreements but also for improving the infrastructure and logistics for the supply.

Together with Pfizer, we are also working with various organizations to support the supply of vaccines to populations worldwide. And we will continue to provide low or lower middle income countries with our vaccine at a not-for-profit price.
JOHNSON & JOHNSON

Johnson & Johnson responded to Amnesty International’s request for comment by email on 14 September 2021 by commenting directly on Amnesty International’s letter. The following provides an overview of Johnson & Johnson’s main comments.

IN RELATION TO JOHNSON & JOHNSON’S HUMAN RIGHTS POLICY
- “Beyond issues of IP and pricing transparency, we have developed and delivered our vaccine in accordance with human rights in other respects as well. For example: we conducted our COVID-19 vaccine trials in lower-income settings and recruited a diverse set of trial participants; and we helped advocate for the implementation of the world’s first vaccine injury compensation mechanism for eligible individuals in 92 Low- and Lower-Middle-Income Countries.”

IN RELATION TO INACTION ON INTELLECTUAL PROPERTY AND TECHNOLOGY SHARING:
- “To the contrary, J&J has been far from inactive with our IP – we have used it to foster innovation and scale manufacturing in the most effective and efficient way to produce the vaccine and address the human right to health. Producing vaccines involves complex manufacturing processes. Globally, there is a limited number of manufacturers with sites capable of producing the high quality and safe vaccines necessary to address this pandemic. In an effort to identify qualified partners, J&J assessed nearly 100 different production sites resulting in 12 partnerships across four continents. Examples include our collaborations with Aspen Pharmacare (South Africa), Biological E. (India), Merck (U.S.) and Sanofi Pasteur (France). Each of these partnerships include a tech transfer component, a manufacturing license to our technology and the sharing of manufacturing know-how to enable the safe and high-quality production of our vaccine and to activate our manufacturing on a global scale as soon as possible. We do not believe that circumventing IP, or the forced sharing of IP, would produce additional manufacturing sites capable of producing safe and effective vaccines and would hinder the ability of companies to enter into the partnerships necessary to scale up vaccine supply. IP has not been a barrier but rather has been a key facilitator of our COVID response at every step of the way.”
- “J&J has established 12 manufacturing and supply partnerships across four continents, each of our manufacturing partnerships is based on a voluntary technology transfer from Johnson & Johnson to its partners. These transfers include a manufacturing license to our technology and the sharing of manufacturing know-how to enable the safe, swift and highest-quality production of our vaccine on a global scale. We have also initiated discussions with Aspen Pharmacare to further expand COVID-19 vaccine production, including a potential commercial license, and we are continuing to assess additional manufacturing opportunities in various regions.”

ON TRANSPARENCY OF CONTRACTUAL TERMS AND CONDITIONS OF PURCHASE AGREEMENTS
- “We have permitted a redacted version of our APA with the European Commission to be published: https://ec.europa.eu/info/sites/default/files/jj_apa_202005071550.pdf”
June 8, 2021

Mr. Patrick Wicken
Head of Business, Security and Human Rights
Amnesty International
Peter Benenson House
1 Easton Street
London WC1X 0DW
United Kingdom

Sent by email to PWicken@amnesty.org

Dear Mr. Wicken:

I write in response to your letter of May 26, 2021 addressed to Stéphane Bancel, Chief Executive Officer of Moderna, Inc. We share your deep concern with the humanitarian and public health crisis posed by the COVID-19 pandemic, particularly in low and middle-income countries, and we agree that it is vitally important to rapidly increase global access to safe, effective vaccines by expanding the production of our COVID-19 vaccine. I hope that the explanations below will help address the questions that you posed in your letter.

Background

I believe it is important to provide some background on the technology and manufacturing processes that are used to produce Moderna's COVID-19 vaccine. Our company was only founded a decade ago, and our COVID-19 vaccine is our first commercial product. Since our founding, our mission has been to improve patients' lives by creating a new generation of transformative medicines based on messenger RNA ("mRNA").

For our first decade, Moderna focused on research and development. We designed our strategy and operations to unlock the potential of mRNA over a long time horizon. We raised billions of dollars in capital and built and invested in our technology platform, which creates mRNA sequences that cells recognize as if they were produced in the body. We have announced twenty-four therapeutic and vaccine development programs to date. These programs span a wide range of conditions, including infectious diseases, immunology, rare diseases, autoimmune diseases, and cardiovascular diseases.

This decade of research taught us valuable lessons about designing mRNA medicines, including vaccines. We learned how to manufacture and formulate mRNA that can be safely injected into people and induce an appropriate immune response. We also gained experience producing over 100 batches of mRNA for use in human clinical trials.

When COVID-19 emerged, Moderna was able to develop our vaccine quickly because we leveraged our prior research, experience, and mRNA platform. We progressed from genetic sequencing to a vaccine ready for human testing in just 63 days. After clinical trials, on December 18, 2020, the U.S. Food & Drug Administration authorized the emergency use
of our COVID-19 vaccine. This was the first time any Moderna product has been authorized for use outside of clinical testing.

Producing a vial of our vaccine is a multiple-stage process. First, we have to create large batches of the drug substance: mRNA encapsulated in a lipid nanoparticle. This first stage is itself a multistep process that requires the availability of raw materials and consumable supplies. The second and third major stages of the production process are filling vials with the drug substance, and then inspecting, testing, and packaging the filled vials for delivery. At any given time, millions of doses of our vaccine will be at different stages of this process.

The pace and volume of our production process has increased exponentially since we began making our vaccine, for several reasons. First, over time, the buildup of the product and other necessary supplies at each stage generally allows subsequent stages to operate more efficiently. Second, the pace also increases as the process gets refined and the highly skilled and experienced personnel operating that process gain greater familiarity with it. Third, as discussed below, we have been able to gradually onboard additional partners to expand our capacity.

Obviously, greater scale and speed cannot come at the expense of safety and quality. Ensuring both requires careful planning and specialized knowledge sharing between Moderna and its contract partners. As such, conducting technology transfers and ramping up new production lines requires significant time from a limited pool of experienced personnel with the requisite expertise.

Notwithstanding these challenges, to date, Moderna has produced and shipped well over 100 million doses of our vaccine, and we currently forecast producing between 800 million to 1 billion doses in 2021.

Expanding Global Vaccine Access

As we have said in recent public statements—both during our Annual Meeting of Shareholders and during our first quarter earnings call—we do not believe that a waiver of the protections under the World Trade Organization ("WTO") Agreement on Trade-Related Aspects of Intellectual Property Rights ("TRIPS") or the contribution of our intellectual property to the World Health Organization's ("WHO") COVID-19 Technology Access Pool ("C-TAP") are effective ways of rapidly expanding access to COVID-19 vaccines. That said, we have undertaken several measures that we believe will meaningfully increase access to vaccines as quickly as possible, as further described below.

Supplying Up To 500 Million Doses To COVAX

On May 3, 2021, we announced that we have entered an agreement to supply up to 500 million doses of our vaccine to COVAX, including an initial 34 million doses to be delivered in the fourth quarter of 2021.1 The agreement covers the 92 Gavi COVAX Advance Market

---

Commitment low- and middle-income countries, and gives Gavi, the Vaccine Alliance, the option to procure 466 million additional doses in 2022. This agreement came just days after the WHO issued an Emergency Use Listing for Moderna’s vaccine, a prerequisite to reaching agreement to supply COVAX. All doses are offered at Moderna’s lowest tiered price.

While most of our efforts to provide our vaccine to low- and middle-income countries have been focused on COVAX, we have also entered into supply agreements with other nations, such as the Philippines, Colombia and Botswana for separate supply. We are in active discussions for supply with the Indian government and additional countries around the world.

**Forming Partnerships to Increase Manufacturing Capacity**

Moderna has entered into voluntary licensing arrangements to manufacture its vaccine and expand supply around the world. In the United States, Moderna’s vaccine is produced both at its own Norwood, Massachusetts facility and at a facility in Portsmouth, New Hampshire operated by our contract manufacturing partner, Lonza Ltd. Moderna has also formed partnerships for the “fill-finish” stages of the process in the United States. That work is done by partners Catalent (in Bloomington, Indiana), Baxter BioPharma Solutions (in Bloomington, Indiana), and Sanofi (in Ridgefield, New Jersey), and we recently announced an intent to further expand this capacity by working with Thermo Fisher Scientific.

Moderna has also entered into partnerships to produce, fill, and finish its vaccine outside the United States. For nearly a year, Moderna has worked with Lonza to produce our vaccine at Lonza’s facility in Switzerland. We recently partnered with Laboratorios Farmacéuticos Rovi in Spain for both the manufacturing and fill-finish process. We have also partnered with Recipharm in France for the fill-finish process.

We are committed to pursuing additional partnerships around the world to expedite production and delivery of our vaccine and we are continuing to seek out such agreements. Moderna is engaged in active conversations with governments and private companies in middle- and low-income countries about partnerships to expand the manufacturing process in those countries.

**Building Capacity to Produce Up to 3 Billion Doses in 2022**

We are also building production capacity here in the United States. On May 4, we announced the expansion of our Norwood, Massachusetts facility, which will more than double its space and transform it from a production and lab space to an industrial technology center. We will increase production and lab space from approximately 300,000 square feet to approximately 650,000 square feet through renovation of existing space and acquisition of a 240,000 square foot building located on the same campus. This expansion will support a 50% increase in production of our vaccine in Norwood.

This investment is part of a broader effort, announced a few weeks ago, to make new funding commitments to increase supply at our owned and partnered manufacturing facilities. We expect these investments and planned partnerships will increase global 2022
capacity to up to 3 billion doses of our vaccine. At the same time, we raised our 2021 manufacturing supply forecast to between 800 million to 1 billion doses.

When completed, the investments will also result in an increase in safety stock of raw materials and finished product used to deliver committed volumes. The company will begin making investments at its owned and partnered manufacturing facilities in 2021, with increased production from these investments expected to ramp up in late 2021 and early 2022.

We have also explored establishing a manufacturing presence in Africa to solve for unmet needs under current vaccine production capacity on the continent.

Addressing Logistical Obstacles Through Science

Moderna is also expanding global access by researching methods to extend vaccine shelf life and reduce the need for temperature-specific storage. These efforts are vital to broadening vaccine distribution in remote areas and developing nations. We recently announced data indicating that the current formulation of our vaccine could support a 3-month refrigerated (2-8°C) shelf life in alternative formats to facilitate easier distribution to doctor’s offices and other smaller settings. Our vaccine is also the only authorized mRNA vaccine that does not require on-site dilution.

We also recently announced that we are working on a next generation vaccine candidate that we believe will extend refrigerated shelf life even further. Moderna’s investments in its mRNA platform enabled development of this next generation vaccine candidate, it is a potential refrigerator-stable vaccine that could facilitate distribution and administration in a wider range of settings, including in developing countries.

Making a Voluntary Pledge on Intellectual Property

Finally, as you noted in your letter, on October 6, 2020—over eight months ago—Moderna voluntarily pledged not to enforce our COVID-19 related patents against those making vaccines intended to combat the pandemic. Our statement noted that Moderna is a pioneer in the development of mRNA vaccines and therapeutics and that, with the support of our investors, we have invested billions of dollars into research and development to make mRNA medicines a reality. We recognized, as a company committed to innovation, that intellectual property rights play an important role in encouraging investment in research.

---

3 Moderna, Press Release: Moderna Announces Additional Investments to Increase Global Supply for COVID-19 Vaccine to up to 3 Billion Doses in 2022 (April 29, 2021), https://investor.modernatx.com/news-releases/news-release-details/moderna-announces-additional-investments-increase-global-supply. The total amount will depend upon the mix between our authorized vaccine at its current dose level and potentially lower doses of our variant booster candidates and pediatric vaccines, if authorized.

We noted that our portfolio of intellectual property is an important asset that will protect and enhance our ability to continue to invest in innovative medicines.

Notwithstanding that, we explained that Moderna "feels a special obligation under the current circumstances to use our resources to bring this pandemic to an end as quickly as possible." We pledged that "while the pandemic continues, Moderna will not enforce our COVID-19 related patents against those making vaccines intended to combat the pandemic." We also stated that "to eliminate any perceived IP barriers to vaccine development during the pandemic period, upon request we are also willing to license our intellectual property for COVID-19 vaccines to others for the post pandemic period."

**Barriers to Vaccine Access**

Your letter asks us why we have not contributed our intellectual property to the WHO's C-TAP. We believe that the best way to expand access to vaccines is by working with proven partners who are capable of producing our vaccine safely and effectively. With respect to mRNA vaccines, our view is that the complexity of the manufacturing process and the need to maintain rigorous safety and quality standards impose real constraints on the rate at which we can increase global supply. These practical constraints require cooperative, collaborative partnerships to overcome. As a result, it takes time and requires human expertise to ramp up new manufacturing lines.

There are additional barriers. Limits on raw materials and consumables, along with other supply chain issues, constrain the pace of production. Logistical challenges—such as the lack of cold storage and transportation and infrastructure problems—pose significant challenges to widespread distribution. Finally, local regulatory requirements and trade hurdles (including tariffs, export restrictions, customs procedures) serve as additional barriers to the effort to quickly vaccinate the global population.

**Additional Intellectual Property and Technology Transfer Issues**

As described above, Moderna has taken major steps to ensure that intellectual property rights are not a barrier to expanding global vaccine access. We have entered into voluntary licensing arrangements, conducted technology transfers, and formed manufacturing partnerships to expand production of our vaccine. We are committed to seeking additional partnerships. We have also voluntarily pledged not to enforce our COVID-19 related patents against those making vaccines intended to combat the pandemic, and we have said that we are willing to license our intellectual property for COVID-19 vaccines to others for the post-pandemic period.

As discussed above, technology transfers require significant time from a limited pool of experienced personnel with the requisite expertise. We are focused on transferring technology to chosen partners around the world—partners that we are confident can produce our vaccine with the utmost commitment to safety and quality. We are prioritizing bringing these manufacturing capabilities and production lines online as quickly as possible. Trying to engage in additional technology transfers could put at risk the delivery of our
current and upcoming production lines and could have negative efficiency, safety, and quality consequences.

We believe that the steps outlined above are the most effective way of expanding the supply of mRNA vaccines in 2021 and 2022. We are not aware of idle mRNA manufacturing capacity. Nor are we aware of companies who have developed manufacturing, purification, and medical processes that would allow them to rapidly run clinical trials and then produce a meaningful supply of mRNA vaccine. As a result, we are focused on the efforts described above to expand global vaccine access, as well as the development of vaccine boosters targeting emerging variants. From a policy perspective, we also believe that weakening intellectual property protections could impede future innovation by making it harder to fund research and development into high-risk, high-reward innovations over a long time horizon.

* * *

At Moderna, we share your concern with the humanitarian and public health crisis posed by the COVID-19 pandemic, particularly in low- and middle-income countries. We agree that it is vitally important to rapidly increase global access to safe, effective vaccines. We are committed to continuing our efforts to expand global vaccine access.

Thank you. We appreciate your willingness to engage constructively on this issue.

Sincerely,

/John Lepore/

John Lepore
SVP Government Engagement

6
June 15, 2021

Mr. Patrick Wilcken  
Deputy Programme Director  
Head of Business, Security, and Human Rights  
International Secretariat  
Amnesty International  
1 Easton Street  
London WC1X 0DW  
United Kingdom

Dear Mr. Wilcken,

Thank you for your letter. We welcome the discussion on human rights and agree on its utmost importance to the healthcare sector. We know there is a lot of interest in every aspect of our work in relation to access to the COVID-19 vaccine and are grateful for all feedback. Before I answer your specific questions, I want to provide more context about our approach to addressing this pandemic.

Pfizer’s purpose — *Breakthroughs that change patients’ lives* — is the driver of everything we do. Equity, among our four Company values¹, determines how we deliver on our purpose and, in consequence, profoundly guides the ways in which we work to fulfill our responsibility to the global community.

You have likely seen in our public statements that our approach to the development of this vaccine was grounded in the hope that the vaccine would be available to every patient, country and community that seeks access.

Our COVID-19 efforts did not happen in isolation. Over the past four years, Pfizer has been engaged in a review of the UN Guiding Principles on Business and Human Rights and what they mean for our business. After assessing with internal and external stakeholders, we concluded that we needed to firmly state that the right to health is the most salient human rights issue for Pfizer, and that more work was needed to demonstrate the steps the company is taking to bring a human rights-based approach to our work. This resulted in revising our [human rights policy statement](https://www.amnesty.org).

---

¹ The four values that guide Pfizer’s culture are Equity, Joy, Excellence and Courage.
With the most vulnerable in mind, we opted for a multi-pronged approach to enable access to our COVID-19 Vaccine:

First, we chose to use a tiered pricing approach that was set based on the income level of each country which allowed Governments to distribute our vaccine to their citizens for free;

Second, we partnered with global health stakeholders to help strengthen healthcare systems where greater support may be needed to deploy COVID-19 vaccines; and,

Third, we continued investing in innovation to enable access, advancing research into the needs of specific populations and of the evolution of the disease.

**Access**

As the pandemic continues, our priority remains the same: *fair and equitable distribution of our COVID-19 vaccine*. To do this, we continue supporting Governments that choose to procure our vaccine by ensuring there is enough supply of vaccines for the government’s needs. We have announced that we will manufacture the world 3 billion doses in 2021, and we anticipate producing 4 billion doses in 2022. These doses are not for the rich or poor, not for the north or south. These are doses for ALL.

Although today most of the approximately 450 million doses we have shipped have gone to high income countries for a variety of reasons (including the time of their regulatory approvals and operational readiness), we actively took action, including me personally, reaching out to Heads of State by letter, phone, and even text, to urge them to reserve doses, to address the risk this imbalance represented to people in lower income countries because the supply was limited. In many cases, Governments had decided to prioritize vaccines from other manufacturers either because mRNA technology was untested at that time, or because they were offered local production options. Some didn’t even approve our vaccine. Unfortunately, other vaccine producers were not able to meet their supply commitments for varying technical reasons. Most of the countries that did not choose us initially came back, and thanks to our phenomenal supply ramp up, we have started signing supply agreements with them. Pfizer also engaged with COVAX since the early phase of the pandemic, and we have put in place extensive support to minimize any barrier to countries receiving our vaccine.

Thanks to all these efforts, we now expect the supply balance to weigh in favor of middle- and low-income countries in the second half of 2021, and to have virtually enough supply in 2022 for all governments that choose to procure our vaccine.

Recently, we pledged to provide 2 billion doses of our COVID-19 vaccine to middle- and low-income countries over the next 18 months. We expect to provide 1 billion of these doses to low- and middle-income countries this year. And we pledged to deliver another 1 billion doses to these countries in 2022. Upon finalization of all agreements, we expect 40% of our planned supply to go to low- and middle-income countries.

On June 10, Pfizer and BioNTech announced plans to provide the U.S. government, at a not-for-profit price, 500 million doses of the companies’ COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic. The government will, in turn, donate the Pfizer-BioNTech vaccine doses to low- and lower-middle-income countries and organizations that support them. Doses will be donated to approximately 100 low- and lower-middle-income countries, including those in the African Union via the COVAX Facility.
Under a previous agreement, Pfizer-BioNTech had allocated doses through COVAX to countries in every region of the world, including Rwanda, Cape Verde, Tunisia, West Bank/Gaza Strip, Angola, Botswana, Colombia, Peru, El Salvador, Bolivia, South Korea, Philippines, Maldives, Pakistan, Laos, Bangladesh, Bhutan, Moldova, Georgia, Ukraine, Bosnia & Herzegovina, Mongolia and Kosovo.

In the next round of COVAX allocations, Pfizer/BioNTech doses will have been allocated to nearly 50 diverse countries and territories through June 2021, and we continue to engage with COVAX in discussions on how to get more doses to more people.

**Pricing model**

In response to your question about Pfizer’s pricing model, please note that we established pricing principles for the COVID-19 vaccine which are consistent with Pfizer’s commitment to the right to health, our values, and our mission to bring breakthroughs that change patients’ lives. These are extraordinary times, and our pricing reflects that. During the pandemic we priced our vaccine consistent with the urgent global health emergency we are facing to help ensure widespread vaccination for all countries that supply our vaccine. Our pricing enables governments to offer the vaccine at little to no out-of-pocket costs for their populations.

And recognizing that equity doesn't mean we give everyone the same, but rather we give more for those in higher need, we set a lower price for middle-income than high-income countries, and we are providing the vaccine to low-income and lower-middle-income countries at a not-for-profit price.

Volume of doses ordered, advance commitments, and equity considerations are key drivers in our government contract pricing. We have a tiered pricing approach that enables poorer countries to pay less, and we also take into account advance commitments and the number of doses contracted.

Pfizer believes it has, and will continue to, engage in transparent and appropriate pricing consistent with Pfizer’s commitment to the right to health, our values, and our mission to bring breakthroughs that change patients’ lives.

Pfizer’s development and manufacturing costs relating to the COVID vaccine have been entirely self-funded. To date, Pfizer has already invested $2 billion in the development of the vaccine. We have invested at risk, and are prepared to continue to bear the costs of development and manufacturing in an effort to advance a solution to this pandemic.

The agreements Pfizer has entered with Governments are for supply of vaccine to their people, not for vaccine development. We have invested from our own resources/flex of revenues at risk, and are prepared to continue to bear the costs of development and manufacturing to advance a solution to the pandemic.

Vaccines offer value to both patients and the public health and are complex to develop, manufacture and distribute. For example, our COVID-19 vaccine involves the use of over 280 materials that come from 36 suppliers in 19 different countries. Post the pandemic, we will utilize a market and value-based pricing approach.

**Intellectual property**

In response to your question about the TRIPS waiver and related lobbying efforts, the IP system is an essential facilitator to the availability of the vaccine and not an impediment or risk, and remains a critical enabler of the future research that will be necessary to end the pandemic. It took not only unprecedented courage and dedication, but also significant investments, at-risk, to bring diagnostics, treatments and now finally vaccines to tackle COVID-19.
The incentives provided by the intellectual property system enabled Pfizer to build the expertise and infrastructure that allowed us to quickly mobilize and devote the resources, technical knowledge and know-how required to combat the pandemic—and it also facilitated the advancement of cutting-edge technologies such as mRNA vaccines. It has enabled an unprecedented number of collaborations between biopharmaceutical innovators and governments, universities, and other research partners to speed up progress on finding solutions to end the pandemic, as demonstrated by our partnership with BioNTech. Under our agreement with BioNTech, the IP directed to the mRNA COVID-19 vaccine is primarily owned by BioNTech.

The TRIPS Agreement, which sets down minimum standards for many forms of intellectual property rights, is critical to lock in the IP protections that will be needed to incentivize innovation and facilitate partnerships, especially as we seek to find solutions for special populations (e.g., children) and overcome new variants of the virus. Not only would waiving those commitments send the wrong message to future innovators in the next pandemic, it could make it harder to resolve the current one, particularly if companies begin to buy up scarce inputs in the hopes of manufacturing a vaccine using technology developed by others. Greater demand pressures on inputs from new market entrants will make it harder, not easier, to manufacture vaccines in the near term.

As indicated in our Environmental, Social & Governance Report, responsible use of our intellectual property (IP) enables us to engage in collaborations and partnerships that have the potential to speed up progress on the most pressing unmet medical needs, including COVID-19. We are proud of our long-standing commitment to keeping patients and societal benefit at the center of our IP practice.

Last month we, along with 25 members of the biopharmaceutical industry, launched the "IP Principles for Advancing Cures and Therapies" (IP PACT)—a groundbreaking, unified declaration of 10 key intellectual property principles that guide our companies’ approach to IP—with patients as our North Star.

Recognizing the unique level of economic development and social challenges of Least Developed Countries, as defined by the United Nations Committee for Development Policy, Pfizer has a general policy of patent non-enforcement in LDCs.

In response to your question regarding the COVID-19 Technology Access Pool, I can say that we have always said that no one company, vaccine or treatment would be enough to combat this pandemic, and that we need to harness the potential of the full biotechnology ecosystem. That is why, in March of last year, we committed to sharing our scientific tools and insights, development expertise, and manufacturing capacity in our 5-Point Plan. We also stood in solidarity with industry leaders and pledged to protect scientific integrity, building on our rich history in vaccine research and development. In that spirit, Pfizer welcomes voluntary initiatives that add to the pool of resources and options available to promote equitable access to COVID-19 therapies and vaccines, and we remain committed to constructive dialogue with all parties. We will continue to consider all reasonable options and mechanisms, as needed, to ensure that the vaccine and any potential therapies to help address the pandemic are accessible to those who need it.

In response to your questions about licensing agreements, knowledge and technology sharing, and due diligence of other solutions to expand manufacturing of COVID-19 vaccine, I can say the development, manufacturing, distribution and storage of complex innovative products, including the mRNA technology, require globally-optimized supply chains and we are actively focused on production arrangements to support a robust and reliable global supply chain. We are one of the few companies that still develop and manufacture vaccines on a large scale. For biologics, sterile injectables and vaccines, we have approximately 17,000 colleagues in 23 manufacturing facilities in 11 countries.
Pfizer is also one of the largest producers of generic sterile injectable products for the US market. We do the vast majority of our sterile filling internally for our branded and generics business, but we do use a great network of outside suppliers that do more specialized sterile filling for us.

Early on, we determined that the best way to manufacture this vaccine at significant scale quickly, and in compliance with all quality standards, would be to activate our extensive manufacturing network in Europe and the US, which includes relying on the thousands of highly skilled workers. At this point, we are favoring global contract manufacturers with broad regulatory approvals and significant available capacity over local contract manufacturers in individual markets. Localizing vaccines requires time consuming processes, as well as a significant commitment of technical and personnel resources, resources that would have to be pulled away from the current production of the vaccine. Therefore, Pfizer currently is focusing our efforts and resources in a way that maximizes our overall supply so we can better support the global needs. While we pursue our current strategy, we also continue to evaluate whether and where localization may be appropriate.

We have undertaken significant efforts to scale up capacity and enhance efficiency. For example, we have added suppliers as well as contract manufacturers, made process improvements to our existing production lines, and we are also making continuous improvements in our sites. We expanded the supply of raw material from existing suppliers and brought on new suppliers. We doubled our batch sizes in order to minimize time between batches and increased the yield per batch. Our efforts to date have paid off: We have increased projected 2021 global production from 1.3 billion doses, to more than 2.5 billion doses. Planning for the future, Pfizer continues to evaluate new manufacturing partners with appropriate manufacturing expertise, technical capabilities, trained personnel, qualified facilities and scientific expertise. All members of our supply chain are expected to operate their businesses in a responsible and ethical manner, respecting human rights, as outlined in Pfizer’s Supplier Code of Conduct.

There is enormous collaboration to overcome existing obstacles already taking place. Manufacturers with the appropriate expertise, technical capabilities, and facilities have entered into partnerships and licensing agreements to speed up the production and distribution of vaccines. For example, ThermoFisher, Sanofi, and Novartis are supporting the Pfizer-BioNTech efforts to increase the supply of our COVID-19 vaccine, which includes expanding our manufacturing facilities, and adding more suppliers and contract manufacturers to our supply chain.

**Continued innovation to enable access**

We continue to study the safety and efficacy of the vaccine. Specifically, we continue advancing the science and knowledge about the impact of our COVID-19 vaccine in specific populations, such as pregnant women and children. We have obtained approval for new storage options to help address distribution challenges, and we are delivering on our commitment to advance our research program for a COVID-19 Antiviral treatment, which is in development.

And beyond efforts around our COVID-19 vaccine, since the beginning of the pandemic, we have been working with governments and international non-governmental organizations to provide relief and support where it is needed through donations of much needed medications and by working to support front line health workers in vulnerable communities.

We are committed to positive health outcomes for people everywhere and continue working to continuously improve wherever we can.
To conclude, we recognize and are concerned by the complex evolution of the pandemic and how it continues to have severe impacts on individuals, families and communities. We continue to regularly evaluate the risks it poses to people, particularly in the most vulnerable geographies, and among the most vulnerable groups of society. No single organization or Company can solve the equity challenge alone.

We are committed to continue evolving and improving our response to this pandemic where we can. For this, we welcome the opportunity to engage with all stakeholders and to listen to external perspectives, such as yours. We value the opportunity to reflect on what we have already achieved, and our lessons learned, and will be continuing this conversation internally in line with our commitment to continuous improvement.

We remain fully focused on getting high-quality, safe and effective vaccines to patients all over the world as quickly as possible and to helping end this deadly pandemic.

Your sincerely,

Albert Bourla

Dr. Albert Bourla, D.V.M., Ph.D.
Chairman of the Board, Chief Executive Officer

ANNEX 3: RESPONSES FROM INSTITUTIONAL INVESTORS

➢ INSERT responses from Baillie Gifford, BlackRock and UBS
AMNESTY INTERNATIONAL
IS A GLOBAL MOVEMENT
FOR HUMAN RIGHTS.
WHEN INJUSTICE HAPPENS
TO ONE PERSON, IT
MATTERS TO US ALL.

THIS IS THE INSIDE BACK COVER
Please do not edit the new global movement statement above “RT Statement” style (except to change to a different language).

Should you need to direct enquiries to a specific regional office, please edit the contact details in the footer. These are embedded in the footer of this page.

TO ACCESS THE FOOTER TEXT BELOW
Go to the ‘Insert’ tab in the ribbon, and choose ‘Footer’ from the Header & Footer segment. Look down the menu of different footers until you find the option to ‘Edit Footer’ near the bottom of the list. Choosing this option allows you to change the text in the footer. Only do this if you need to change the language or if you are sure about needing to use different contact details.

Please note that the Amnesty Twitter handle is now just ‘@Amnesty’ so you should no longer use the older version, ‘@Amnestyonline’

FOLLOW INSTRUCTIONS THEN DELETE THIS TEXT BOX
A DOUBLE DOSE OF INEQUALITY:

PHARMA COMPANIES AND THE COVID-19 VACCINES CRISIS

The rapid development of effective Covid-19 vaccines in 2020 gave hope to the world in the darkest days of the deadly pandemic. However, the vaccine roll-out has been massively skewed towards wealthy nations. While rich states have hoarded vaccines, companies have also played a decisive role in restricting fair access to a life-saving health product. This report focuses on six leading vaccine developers, AstraZeneca, BioNTech, Johnson & Johnson, Moderna, Novavax and Pfizer, assessing each company’s human rights policy, pricing structure, records on intellectual property, knowledge and technology-sharing, allocation of available vaccine doses and transparency. The report finds that vaccine developers have monopolized intellectual property and blocked technology transfers. Some companies have charged high prices for their vaccines, sold predominantly to rich countries, and stand to make enormous profits - despite receiving billions in public funding. While the vaccine developers claim to respect human rights, all of them - to differing degrees – have failed to meet their responsibilities.